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 Abbreviations 
 
- Aa  : acetic acid 
- ADMA : Asymmetric dimethylarginine 
- An  : acetonitril 
- ATP : Adenosine triphosphate 
- BHMT : Betaine:homocysteine methyltransferase 
- BLB : blood lysis buffer 
- CbI : Methylcobalamine 
- CBS : Cystathionine β-synthase 
- CH2-THF : 5,10-methylene-tetrahydrofolate 
- CH3-THF : Methyletetrahydrofolate 
- Cho : Cholesterol  
- Con : Control group 
- CV : coefficient of variation 
- Cys : Cystathionine 
- DTT : 1,4-dithiothreitol 
- EC  : Eclampsia  
- EC-SOD : Extracellular superoxide dismutas  
- EDTA : Ethylenediamine tetraacetic acid 
- eNOS : NO synthase 
- g  : gram 
- GC-MS : Gas chromatography-mass spectrometery 
- h  : hours 
- Hcy : Homocysteine 
- HELLP : Hemolysis, Elevated Liver enzymes, and Low Platelet count 
- HHcy : Hyperhomocysteinemia 
- HLD : High density lipoprotein 
- HPLC : High Performance Liquid Chromatography 
- ISSHP : International Society for the Study of Hypertension in Pregnancy 
- IUGR : Intrauterin growth retardation 
- LDH : Lactate dehydrogenase 
- MAT : Methionine adenosyltransferase  
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- meth : methanol 
- Meth : Methionine 
- min : minutes  
- MMA : Methylmalonic acid 
- MS : Methionine synthase 
- MTBDSFA: N-methyl-N (tert-butyldimethylsilyl) rifluoracetamide 
- MTHFR : Methylenetetrahydrofolate reductase  
- NF-κB : Nuclear factor- B 
- NHBPEP : National High Blood Pressure Education Program Working Group     
on High Blood Pressure in Pregnancy 
- NO : Nitric oxide  
- NOS : Nitric oxide synthesis  
- NP  : non-pregnant women  
- ONOO־ : Peroxynitrite 
- PARP : Poly (ADP-ribose) polymerase 
- PCR : Polymerase Chain Reaction 
- PE  : Preeclampsia 
- PGL2 : Prostacyclin 
- PLP : pyridoxal-5- phosphate 
- PN.HCL : pyridoxine.HCl 
- RFLP : Restriction Fragments Length Polymorphism method 
- ROS : Reactive Oxygen Species 
- s  : second 
- SAH : S-adenosylhomocysteine 
- SAM : S-adenosylmethionine 
- SDS : sodium dodecyl sulphate 
- SGOT : serum glutamic-oxaloacetic transaminase 
- SGPT : serum glutamic-pyruvic transaminase  
- SH  : sulfuhydryle group 
- SHMT : Serine hydroxymethyltransferase 
- -S-S- : disulfide groups 
- TG  : triglyceride 
- TH  : transient hypertension 
- tHcy : total homocysteine 
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- THF : Tetrahydrofolate 
- TNF- α : Tumor necrosis factor-α 
- Vit B12 : vitamin B12 
- Vit B6 : vitamin B6 
- wk  : week 
- WLB : white lysis buffer 
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SUMMARY 
 
Low maternal B-vitamins status and hyperhomocysteinemia have been related to several 
pregnancy complications and adverse outcomes. Several prospective, retrospective, and case-
control studies provided evidences that indicate the involvement of hyperhomocysteinemia in 
the etiology of preeclampsia, since endothelial dysfunction is a major complication in this 
disease. So far, low B-vitamin status is the most common cause of hyperhomocysteinemia. In 
Syria, a high prevalence of hyperhomocysteinemia and B-vitamin deficiency were found, 
which were mostly attributed to the Syrian lifestyle. Furthermore, low B-vitamin status and 
hyperhomocysteinemia have been described as independent risk factors for coronary heart 
diseases and venous thrombosis in this population.  
Aiming to investigate the role of low maternal B-vitamin status and hyperhomocysteinemia in 
complicated pregnancies in Syria, maternal B-vitamin (folate, vitamin B12, vitamin B6) and 
related metabolic markers, including homocysteine, cystathionine, and methylmalonic acid 
were measured in a group of Syrian normotensive pregnant women and those whose 
pregnancy was complicated with preeclampsia.  
Twelve-hour fasting blood samples were obtained from normotensive pregnant women (n = 
98; 29 to 40 gestational weeks; 19 to 36 years old), and preeclamptic women (n = 177; 30 to 
40 gestational weeks; 18 to 38 years old) of the same socio-economic status. Serum 
concentrations of homocysteine, cystathionine, and methylmalonic acid were assessed by gas 
chromatography-mass spectrometry. Vitamin B12 and folate in serum were measured by 
chemiluminescence immunoassay. The concentration of vitamin B6 was determined in 
plasma using high-performance liquid chromatography methods. Plasma concentration of 
holotranscobalamin П was measured using a radioimmunoassay kit. The C677T 
methylenetetrahydrofolate reductase (MTHFR) gene mutation was investigated using a 
polymerase chain reaction/restriction fragment length polymorphism method. Other 
parameters were measured in Syria using Hitachi 917 automated analyser. 
Higher concentrations of homocysteine, cystathionine, and methylmalonic acid were closely 
linked to a lower status of the B vitamins. In healthy pregnant women, homocysteine 
concentrations increased significantly with increasing gestation (from 5.6 to 8.0 µmol/L). 
Increased tHcy concentrations was associated with decreased serum folate concentrations by 
about 46 % (from 18.6 to 10.1 ng/ml), whereas vitamin B12 concentration displayed a small 
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decrease, only about 17 %. Serum homocysteine and cystathionine concentrations were 
significantly higher (median homocysteine 9.3 versus 6.0 µmol/L; median cystathionine 284 
versus 232 nmol/L) and serum folate concentrations were significantly lower (median folate 
7.3 versus 15.9 ng/ml) in preeclamptic women as compared to controls. These differences 
between patients and controls were seen in each tertile of gestation age. Preeclamptic women 
were more likely to have folate deficiency compared to healthy pregnant women (19 % of 
patients versus 5 % of controls). A very high prevalence of vit B12 deficiency was found in 
both groups, indicated by elevated methylmalonic acid (58.6 % in controls and 68.0 % in 
patients) and low holotranscobalamin П concentrations (76.2 % in controls and 78.6 % in 
patients). Maternal vitamin B6 concentrations were abnormal low and correlated inversely 
and significantly to cystathionine in both groups. The frequency of the homozygous genotype 
of methylenetetrahydrofolate reductase (MTHFR TT) in preeclamptic women was not 
significantly different from that in healthy pregnant women (6.9 % compared with 12.4 %). 
The influence of MTHFR TT genotype on homocysteine concentrations was found to be 
dependent on folate status. Pregnant women with homozygous genotype had significantly 
higher homocysteine concentration compared to those with wild-type genotype (CC) only 
when serum folate concentrations were below 8.9 ng/ml. An increase in the risk of 
hyperhomocysteinemia was associated with folate levels ≤ 8.9 ng/ml and methylmalonic acid 
≥ 339 nmol/L, and this risk was increased progressively when low folate status accompanied 
with elevated methylmalonic levels. Furthermore, there was statistically no significant 
association between the maternal MTHFR genotype or decreased vitamin B6 levels and the 
risk of hyperhomocysteinemia. There was an association between maternal homocysteine or 
folate concentrations and risk of preeclampsia. Pregnant women with serum homocysteine 
concentration > 7.8 µmol/L or folate concentrations < 8.7 ng/ml experienced a 21.6-fold and 
9.9-fold, respectively, increase in the risk of preeclampsia. There was statistically no 
significant association between the maternal MTHFR genotype or decreased vitamin B12 
levels and the risk of preeclampsia.  
Elevated serum concentrations of homocysteine, cystathionine, and methylmalonic acid in 
preeclamptic women suggest disturbed homocysteine metabolism due to poor status of the B 
vitamins. Higher homocysteine concentrations in preeclamptic women are due to lower folate 
status. In preeclamptic women lower vit B12 concentration causes folate trap resulting in 
increased folate requirement for efficient remethylation of homocysteine to methionine. 
Higher cystathionine concentration in Syrian preeclamptic women is due to insufficient 
vitamin B6 concentration associated with increased activation of transsulfuration pathway due 
6 
to oxidative stress. Increased the risk of preeclampsia with increased homocysteine levels 
confirms the aetiological role of homocysteine in preeclampsia by inducing endothelial 
dysfunction. 
Finally, the poor nutritional status in Syrian women, which is attributed to Syrian lifestyle,  
and associated hyperhomocysteinemia seem to be important factors in preeclampsia. 
Therefore, the improvement of B-vitamin status by supplementation is necessary to prevent 
pregnancy complications in women of childbearing age in this population. However, in 
populations with a high prevalence of vitamin B12 deficiency, like our population, vitamin 
B12 supplementation, in addition to folate supplementation, should be considered in order to 
improve vitamin status and lower homocysteine levels. 
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ZUSAMMENFASSUNG 
 
Erniedrigte B-Vitamine und die Hyperhomocysteinämie wurden mit verschiedenen 
Schwangerschaftskomplikationen und einem ungünstigen Verlauf in Zusammenhang 
gebracht. Verschiedene prospektive, retrospektive und Fall-Kontroll Studien weisen auf eine 
Beteiligung der Hyperhomocystenämie bei der Ätiologie der Präeklampsie hin, zumal die 
endotheliale Dysfunktion für die Pathophysiologie dieser Erkankung eine zentrale Rolle 
spielt. In Syrien wurde eine hohe Prävalenz der Hyperhomocysteinämie und des Vitamin B 
Mangels gefunden, was im wesentlichen auf die syrische Lebensführung zurückzuführen ist. 
Außerdem wurden der Vitamin B-Mangel und die Hyperhomocysteinämie als unabhängige 
Risikofaktoren für kardiovaskuläre Erkrankungen und für venöse Thrombosen in dieser 
Bevölkerung beschrieben. 
Um die Bedeutung des niedrigen mütterlichen Vitamin B-Status und der 
Hyperhomocysteinämie bei Schwangerschaftskomplikationen in Syrien zu untersuchen, 
wurden die mütterlichen B-Vitamine (Folat, Vitamin B12 und Vitamin B6) und die 
Metaboliten Homocystein, Cystathionin und Methylmalonsäure in syrischen normotensiven 
Schwangeren und Präeklampsie Patientinnen gemessen. 
Nach zwölfstündigem Fasten wurden Blutproben von normotensiven Schwangeren (n = 98; 
29. bis 40. Schwangerschaftswoche, Alter: 19 – 36 Jahre) und präeklamptischen Schwangeren 
(n = 177; 30. – 40. Schwangerschaftswoche; Alter: 18 – 38 Jahre) mit gleichem 
sozioökonomischen Status entnommen. Die Serumkonzentrationen des Homocysteins, 
Cystathionins, und der Methylmalonsäure wurden mit Hilfe einer Gaschromatographie-
Massenspektrometrie-Methode bestimmt. Vitamin B12 und Folat im Serum wurden mit 
einem Chemilumineszenz-Immunoassay gemessen. Die Vitamin B6 Konzentration wurde mit 
einer Hochleistungs-Flüssigkeitschromatographie-Methode bestimmt. Die Plasmakonzentra-
tionen des Holotranscobalamin II wurden mit einem Radioimmunoassay gemessen. Die 
C677T Methylentetrahydrofolat-Reduktase (MTHFR) Genmutation wurde mit der 
Polymerasekettenreaktion und einem Restriktionsenzym-Fragmentlängen-Polymorphismus 
untersucht. Weitere Parameter wurden in Syrien mit einem Hitachi 917 Analyseautomaten 
gemessen. 
Erhöhte Konzentrationen des Homocysteins, Cystathionins und der Methylmalonsäure waren 
eng mit einem niedrigen Vitamin B-Status assoziiert. In gesunden schwangeren Frauen 
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stiegen die Homocysteinkonzentrationen signifikant mit zunehmender Dauer der 
Schwangerschaft an (5.6 bis 8.0 µmol/l). 
Erhöhte Homocysteinkonzentrationen waren mit erniedrigten Serumfolatkonzentrationen von 
etwa 46 % (18.6 – 10.1 ng/ml) assoziiert, wohingegen die Vitamin B12 Konzentrationen nur 
einen kleinen Abfall von etwa 17 % zeigten. Die Homocystein und Cystathionin 
Konzentrationen waren signifikant höher in den Präeklampsie-Patientinnen im Vergleich zu 
den Kontrollen (mediane Homocysteinkonzentrationen 9.3 gegenüber 6.0 µmol/l; mediane 
Cystathioninkonzentrationen 284 gegenüber 232 nmol/l), während die Serumfolat 
Konzentrationen in den Präeklampsie Patientinnen im Vergleich zu den Kontrollen signifikant 
niedriger waren (mediane Folatkonzentrationen 7.3 gegenüber 15.9 ng/ml). Diese 
Unterschiede zwischen Patienten und Kontrollen wurden in allen Terzilen der 
Schwangerschaftsdauer beobachtet. Ein Folatdefizit wurde häufiger bei Präeklampsie 
Patientinnen als bei gesunden Schwangeren gefunden (19 % gegenüber 5 %). Eine sehr hohe 
Prävalenz eines Vitamin B12 Defizits, das durch erhöhte Methylmalonsäurekonzentrationen 
(58.6 % in Kontrollen und 78.6 % bei Patientinnen) und niedrige Holotranscobalamin II 
Konzentrationen (76.2 % in Kontrollen und 78.6 % in Patientinnen) angezeigt wurde, konnte 
in beiden Gruppen gefunden werden. Die mütterlichen Vitamin B6 Konzentrationen waren 
ungewöhnlich niedrig und korrelierten invers und signifikant mit der Cystathioninkonzentra-
tion in beiden Gruppen. Die Prävalenz für das homozygote Vorliegen der Mutation der 
Methylentetrahydrofolatreduktase (MTHFR 677TT) unterschied sich nicht signifikant 
zwischen den Präeklampsie-Patientinnen und den Kontrollen (6.9 % gegenüber 12.4 %). Der 
Einfluss des MTHFR Genotyps auf die Homocysteinkonzentration war vom Folat Status 
abhängig. Schwangere Frauen mit homozygotem Genotyp hatten nur dann eine signifikant 
höhere Homocysteinkonzentration im Vergleich zu denen mit dem Wildtyp-Genotyp (CC), 
wenn die Serumfolatkonzentration unter 8.9 ng/ml lag. Eine Zunahme des Risikos für eine 
Hyperhomocysteinämie war mit Folatspiegeln ≤ 8.9 ng/ml und Methylmalonsäurekonzentra-
tionen ≥ 339 nmol/l assoziiert. Außerdem wurde das Risiko für eine Hyperhomocysteinämie 
besonders stark erhöht, wenn bei niedrigem Folat Status gleichzeitig die Methylmalonsäure 
erhöht war. Es war bestand keine signifikante Assoziation zwischen dem mütterlichen 
MTHFR Genotyp bzw. dem erniedrigtem Vitamin B6 Spiegel und dem Risiko der 
Hyperhomocysteinämie. Es bestand eine Assoziation zwischen dem Risiko für die 
Präeklampsie und dem mütterlichen Homocysteinspiegel sowie dem Folatspiegel. 
Schwangere Frauen mit Serumhomocysteinkonzentrationen > 7.8 µmol/l oder Folatkonzentra-
tionen < 8.7 ng/ml hatten ein 21.6 fach bzw. 9.9 fach erhöhtes Risiko für die Präeklampsie. 
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Der mütterliche MTHFR Genotyp und erniedrigte Vitamin B12-Spiegel waren nicht 
signifikant mit der Präeklampsie assoziiert. 
Die erhöhten Serumkonzentrationen des Homocysteins, Cystathionins und der 
Methylmalonsäure bei Präeklampsie Patientinnen legen einen aufgrund eines defizitären 
Vitamin B-Status gestörten Homocystein Metabolismus nahe. Die höheren Homocysteinko-
nzentrationen in Präeklampsie Patientinnen sind auf einen erniedrigten Folat Status 
zurückzuführen. In Präeklampsie Patientinnen verursacht erniedrigtes Vitamin B12 eine Folat 
Falle, die einen erhöhten Folat Bedarf für eine effiziente Remethylierung des Homocysteins 
zum Methionin zur Folge hat. Die erhöhte Cystathioninkonzentration in syrischen 
Präeklampsie Patientinnen ist auf eine inadäquate Vitamin B6 Konzentration und eine 
Aktivierung des Transsulfurierungsweges aufgrund von oxidativen Stress zurückzuführen. 
Das mit steigenden Homocysteinspiegeln zunehmene Präeklampsierisiko bestätigt die 
ätiologische Bedeutung des Homocysteins für die endotheliale Dysfunktion bei der 
Präeklampsie. 
Der unzureichende Ernährungszustand der syrischen Frauen, der auf die syrische 
Lebensführung zurückzuführen ist, und die damit einhergehende Hyperhomocysteinämie sind 
wichtige Faktoren für die Präeklampsie. Daher ist eine Verbesserung des Vitamin B-Status 
durch Supplementation notwendig, um Schwangerschaftskomplikationen bei Frauen im 
gebärfähigen Alter in dieser Bevölkerung zu verhindern. Jedoch sollte in einer Bevölkerung 
mit hoher Prävalenz des Vitamin B12 Mangels zusätzlich eine Vitamin B12 Supplementation 
zur Folat Supplementation in Betracht gezogen werden, um den Vitamin Status zu verbessern 
und den Homocysteinspiegel zu senken. 
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01. INTRODUCTION 
 
Pregnancy is a physiological process comprising fundamental changes in the female 
organism. In most women these pregnancies associated changes are well tolerated. However 
in more than 40 % of all pregnant women complications occur. Pregnancy associated 
complications range from marginal pigmentations of the skin to the death of mother and fetus. 
Hypertensive disorders are very frequent complications during pregnancy and may cause 
severe fetal and maternal consequences. Low maternal B-vitamins status and 
hyperhomocysteinemia have been related to several pregnancy complications and adverse 
outcomes. Several prospective, retrospective, and case-control studies provided evidences that 
indicate the involvement of hyperhomocysteinemia in the etiology of preeclampsia, since 
endothelial dysfunction is a major complication in this disease. So far, low B-vitamin status is 
the most common cause of hyperhomocysteinemia. In Syria, a high prevalence of 
hyperhomocysteinemia and B-vitamin deficiency were found, which were mostly attributed to 
the Syrian lifestyle. 
 
1. 1. Homocysteine story 
In 1962, Carson and Neill, (1962) suggested for the first time an association between elevated 
homocysteine (Hcy) levels and diseases. In mentally retarded children they observed elevated 
Hcy levels in plasma and urine. Two years later, Mudd et al. and Gibson et al. noted that the 
homozygous defect of the cystathionine β-synthase is associated with an increased risk for 
death at very young age. However, that time there was no logical explanation for this 
observation. Based on findings obtained from infants with homocystinuria and methylmalonic 
aciduria, who died at 7 weeks of age, McCully hypothesized that elevated Hcy levels causes 
vascular changes and subsequent thrombosis (McCully et al., 1969). The potential role of Hcy 
in atherothrombotic disease has drawn the attention of scientists from many fields. In the 
meantime numerous studies considering Hcy and various diseases have been published. 
Recently, hyperhomocysteinemia is known as a risk factor for cardiovascular disease (Wald et 
al., 2002; Herrmann et al., 2001; McCully KS., 1996; Boushey et al., 1995), adverse 
pregnancy complications (Nelen et al., 2001; 2000; Aubard et al., 2000; Vollset et al., 2000), 
and neuropsychiatric disorders such as Alzheimer’s disease (Schroecksnadel et al., 2004; 
Morris MS., 2003; Nilsson et al., 2002), and immune activation (Schroecksnadel et al., 2004 
a). 
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1. 2. Homocysteine: its forms and related thiols 
The non-proteine forming amino acid Hcy is a byproduct of the degradation of methionine 
(Meth) into the nonessential aminothiol cysteine. Normally, Hcy is metabolized via two 
pathways: the remethylation and transsulfuration pathways (figure 1. 3). Meth is an essential 
protein forming amino acid, which is mainly obtained by food intake or remethylation of Hcy 
(Mudd et al., 2001). Structurally, Hcy closely resembles Meth and cysteine (figure 1. 1).  
   
 
 
 
NH3+     NH3+    NH3+ 
│     │    │ 
CH─CH2—CH2—S—CH3                     CH—CH2—CH2—SH CH—CH2—SH 
│     │    │ 
COO -     COO -    COO – 
 
Methionine    Homocysteine  Cysteine 
 
  
 
NH3+        NH3+ 
│        │ 
CH—CH2—S —CH2 —CH2—CH        
│        │ 
COO -        COO -  
 
Cystathionine               Homocysteine thiolactone 
 
  
    
Figure 1. 1. The formulas of methionine, homocysteine, cysteine, and cystathionine 
 
 
 
Hcy is synthesized within the cell. Due to its toxicity, the intracellular Hcy concentration is 
precisely regulated, < 1 µmol/L, and any excess is exported into the extracellular 
compartments. Because of the sensibility of the sulfuhydryle groups (-SH) to oxidation, only 
1 % to 2 % of total plasma Hcy is found in the reduced form L-homocysteine. The remaining, 
98 %, occur in the oxidized disulfide form (Hcy and mix disulfide) (Ueland PM., 1995; 
Jacobsen et al., 2001; 1998; Mudd et al., 2000). The disulfide form of Hcy is either formed by 
autooxidation or reaction with other thiol-containing compounds, (-SH) or disulfide (-S-S-) 
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groups (Bourdon and Blache, 2001). However, the oxidized forms of Hcy are divided into 
free and protein-bound forms. The free oxidized forms refer to the non-protein bound 
disulfides which include either the homocystine, symmetrical disulfide of two Hcy molecules, 
or the mixed disulfide of Hcy with free cysteine. In contrast, protein-bound Hcy includes 
mixed disulfides of Hcy with plasma proteins containing free cysteine (Mansoor et al., 1992) 
(figure1. 2). The total Hcy (tHcy) concentration refers to all Hcy species existing in plasma. 
Another Hcy derived thiol compound is Hcy-thiolactone. It is a highly reactive intra-
molecular thioester of Hcy. It occurs in all cells and causes homocysteinylation of cellular and 
extracellular proteins that lead to impaired function (Jakubowski et al., 2004; 2000). Increased 
Hcy levels cause a great activation of Hcy-thiolacton production. The detoxification of Hcy-
thiolactone is mediated by the thiolactonase enzyme, a constituent of high density lipoproteins 
(Jakubowski H., 2000 a; 2000 b). 
 
 
 
І REDUCED FORM 
 
- Homocysteine   NH3+ ─CH─CH2─CH2─SH 
 (1-2 %)       l 
        COO – 
Π OXIDIZED FORMS  
 
• Free forms 
      
- Homocystine   NH3+─CH─CH2─CH2─S─S─CH2─CH2─CH─NH3+
 (5-10 %)     l                l  
     COO -              COO – 
 
 
- Homocysteine-cysteine  NH3+ ─CH─CH2─CH2─S─S─CH2─CH─NH3+ 
 (5-10 %)      l      l  
       COO -                COO – 
• Protein-bound form 
 
- Protein-homocysteine NH3+ ─CH─CH2─CH2─S─S─ 
 (80-90 %)     l     
      COO – 
 
 
Figure1. 2. Illustration of all forms of Hcy present in plasma. The percentage of each form in 
plasma is given in brackets 
Protein 
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1. 3. Homocysteine metabolism  
Hcy is the final product of the Meth metabolism, and can be metabolized by two biochemical 
pathways: remethylation and transsulfuration. The remethylation converts Hcy back to Meth 
and the transsulfuration degrades Hcy into cystathionine (Cys) and further more to cysteine 
and taurine. Although Hcy is not a protein forming amino acid, it is involved in many 
important processes: cysteine and glutathione synthesis (Mosharov et al., 2000); catabolism of 
choline and betaine; and recycling of intercellular folates. Cellular Meth can be used for 
protein synthesis or be converted to S-adenosylmethionine (SAM). This reaction is catalyzed 
by the Meth adenosyltransferase (MAT) (figure 1. 3) (Storch et al., 1990), and requires the 
presence of adenosine triphosphate (ATP) (Markham et al., 1980). MAT activity is 
significantly regulated by the intracellular SAM level. SAM has a vital role throughout the 
body (Clarke and Banfield, 2001), particularly in central nerves system: It donates a methyl 
group for a lot of different reactions e.g. synthesis of creatine, phosphatidylcholine, and 
polyamines (for cell growth, gene expression, etc.); methylation of the CpG island of DNA 
(Katz et al., 2003), and acts as a precursor for the synthesise of cysteine and glutathione 
(Bottiglieri T., 2002) (figure 1. 3). The loss of this methyl group converts SAM into S-
adenosylhomocysteine (SAH). SAH is then hydrolysed into adenosine and Hcy. This 
reversible reaction is catalysed by the SAH-hydrolase. The regeneration of Meth from Hcy is 
catalysed by two different methyltransferase enzymes. The first one is betaine:homocysteine 
methyltransferase (BHMT), which is located in liver and kidney. This enzyme utilizes betaine 
(trimethyl-glycine) as a donor of methyl groups. In cases of folate and/or cobalamin 
deficiency, this pathway maintains the tissue concentration of Meth. The second enzyme is 
methionine synthase (MS), also known as 5-Methyltetrahydrofolate:homocysteine 
methyltransferase. MS is present in almost all the cells throughout the body and catalyses the 
transfer of a methyl group from methyletetrahydrofolate (CH3-THF). The remethylation by 
MS needs methylcobalamine as a cofactor (Banerjee et al., 2003; 1990: Matthews RG., 2001) 
(figure 1. 3). The cobalamin-dependent remethylation links the vitamin B12 (vit B12) 
metabolism with the folate cycle. Genetic or acquired inhibition of this enzyme will block the 
incorporation of CH3-THF into the Meth cycle and cause mild hyperhomocysteinemia. 
The transsulfuration pathway occurs only in liver, kidney, small intestine, and pancreas tissue. 
Cysteine and taurine are essential products of the transsulfuration which are centrally 
involved in cardiac and hepatic metabolism as well as in glutathione production. The 
transsulfuration is catalyzed by two pyridoxal phosphate-dependent enzymes (Mudd et al., 
1989): cystathionine β-synthase (CBS) and cystathionine γ-lyase. CBS catalyses the 
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irreversible condensation of serine and Hcy to form Cys, and cystathionine γ-lyase hydrolysis 
Cys to cysteine and α-ketobutyrate (figure 1. 3). Cysteine undergoes further degradation to 
taurine, glutathione, and inorganic sulfur, which is excreted in the urine. CBS contains heme 
as a prosthetic group that is necessary to bind the active form of vitamin B6 (vit B6) (Meier et 
al., 2001; Kery et al., 1994).  
In healthy individuals, the balance between transsulfuration and remethylation pathways is 
highly regulated and mainly employed to insure sufficient amounts of intracellular SAM 
(Finkelstein JD., 2000). In the case of decreased intracellular Meth (e.g. fasting state) 
remethylation is activated and transsulfuration activity becomes down regulated. In such a 
situation only 10 % of Hcy is catalyzed by CBS. The cellular folate cycle is shifted towards 
the formation of CH3-THF. Thereby, utilization of the Meth for purine and pyrimidine 
biosynthesis is reduced (Scott et al., 1983). Contrary a Meth-rich diet will increase SAM 
levels within the cells. SAM then upregulates the CBS activity driving Hcy into the 
transsulfuration pathway (Finkelstein JD., 2000a; 2000b; 1984; Mato et al., 2002; Janosik et 
al., 2001). Additionally, SAM acts as an allosteric inhibitor for methylenetetrahydrofolate 
reductase (MTHFR) and BHMT causing aberration in the remethylation pathway (Jencks and 
Matthews, 1987). Moreover, an increased SAM level causes an increased cellular SAH 
concentration (figure 1. 3), which is a strong inhibitor of the adenosyl methionine-dependent 
methyltransferases. However, it is estimated that Hcy is recycled to Meth several times before 
it becomes irreversibly degraded by the transslfuration pathway (Mudd et al., 1980).  
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Figure 1. 3. Methionine metabolism. BHMT: Betaine:homocysteine methyltransferase, CBS:  
cystathionine B-synthase (vit B6-dependent), MAT: Methionine adenosyltransferase, MS: 
Methionine synthase (vit B12-dependent), THF: Tetrahydrofolate, A: Methyl-Transferases 
B: 5,10-Methylen-THF-Reductase 
 
 
 
A main regulator of Hcy degradation is the folate cycle. Folate, a water-soluble B vitamin, 
acts as a coenzyme to accept or donate one carbon units needed in several metabolic 
pathways: remethylation of Hcy to generate Meth, the synthesis of thymidylate and purines, 
and the formation of methyl group. The first step in the folate cycle is the conversion of 
tetrahydrofolate (THF) to 5,10-methylene-THF (CH2-THF) using serine as a source of carbon 
units and vit B6-dependent serine hydroxymethyltransferase (SHMT) enzyme. A portion of 
the produced CH2-THF undergoes irreversible reduction to CH3-THF via MTHFR. CH3-THF 
is the only circulating form of folate, and is used for the remethylation of Hcy to Meth. As 
shown, folate, vit B12, and MS work together within the cells and their work is tightly 
regulated. Fasting plasma Hcy is markedly increased in patients with folate (Stabler et al., 
1985; Kang et al., 1987) or cobalamin deficiency (Stabler et al.,1985) but is usually normal in 
vit B6-deficient subjects (Miller et al., 1992). Defects in one or more of them cause serious 
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problem. For instance, the genetic defect of MS or the deficiency of vit B12 leads to a trap of 
CH3-THF within the cells. This makes CH3-THF unable to be recycled again into the pool of 
active folates, i.e. “biologically dead”. The consequence are abnormal levels of the 
intracellular folate in the presence of normal or elevated circulating folate levels. Moreover, 
the blocked THF regeneration leads to a reduced thymidylate synthesis causing megaloplastic 
anemia (Hoffbrand and Jackson, 1993). 
 
1. 4. Hyperhomocysteinemia (HHcy) 
HHcy is a terminology suggested to describe the presence of abnormal elevation in tHcy 
levels. Normal range for tHcy concentration is not totally specified although others tend to 
consider values between (5-12 µmol/L) as normal. However, according to the D.A.CH.-Liga 
Homocysteine (German, Austrian, and Swiss Homocysteine Society) fasting tHcy (< 12 
µmol/L) is considered safe and should be the target level during homocysteine-lowering 
treatment. D.A.CH.-Liga Homocysteine classified several types of HHcy according to fasting 
tHcy levels: 
- Moderate HHcy is defined as tHcy concentrations between 12-30 µmol/L and has a 
prevalence of 5-10 % in total population. Unhealthy lifestyle, vegetarian diet, impaired 
renal function, mild folate or vit B12 deficiency, and MTHFR 677 C→T polymorphism 
are common causes for moderate HHcy.   
- Intermediate HHcy is defined as tHcy concentrations between 30-100 µmol/L and its 
prevalence in general population is ~ 1 %. Moderate to severe deficiency of vit B12 or 
folic acid and renal failure can cause intermediate HHcy. 
- Severe HHcy is defined as tHcy concentrations higher than 100 µmol/L and has a 
prevalence of 0.02 %. This form is seen in individuals with homocystinuria or severe vit 
B12 deficiency . 
It is important to mention that the above reported values identifying different types of HHcy 
are commonly used in a non-pregnant population. Normal pregnancy is associated with lower 
tHcy levels compared to non-pregnant state. Therefore, applying these values on pregnant 
women leads to misleading interpretation. HHcy, however, is a controversial term, and the 
cut-off value differs according to the population. Elevated tHcy levels is a proxy measure for 
the deficiency of the B vitamins. Therefore, identifying the cut-off value of HHcy should be 
achieved in the light of B-vitamin status. Up to date, no cut-off value identifying HHcy in 
pregnant women is available. In the current study, the cut-off value (Hcy > 8.2 µmol/L) 
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representing the 95th percentile of Hcy distribution in normotensive pregnant women who had 
adequate status of folate and vit B12 was used. 
 
1. 5. Factors influencing homocysteine concentration 
The regulation of the Meth cycle and the Hcy pathway is tightly associated with the 
availability of folate, vit B6, and vit B12. While folate donates its methyl for the 
remethylation of Hcy, vit B 12 and B6 are important co-factors for MS and CBS, respectively. 
Additionally, there are many other factors influencing Hcy which can be classified as: 
● Physiologic determinants: such as sex (Selhub et al., 1999), age (Selhub et al., 1999; 
Andersson et al., 1992), race (Ubbink et al., 1995), and pregnancy (Kang et al., 1986).  
● Lifestyle factors: such as coffee consumption (Husemoen et al., 2004), alcohol drinking 
(de Bree et al., 2001 a), and physical activity (Herrmann et al., 2003; Nygard et al., 1995).  
● Genetic factors: such as CBS enzyme (Kraus et al., 1999), MTHFR enzyme (Rozen R., 
1997), MS enzyme (Leclerc et al., 1996), and methionine synthase reductase enzyme 
(Matthews et al., 1998). 
● Drugs: Such as lipid lowering drugs, hormons, antiepileptic drugs. For more details the 
reader is referred to the paper of Stanger et al. (2003). 
● Diseases: For details see table (1. 1).  
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Table 1. 1. Diseases affecting Hcy metabolism 
↑ increase; ↓ decrease 
 
 
 
1. 6. Pathogenetic mechanism of homocysteine 
Since McCully`s observation in 1969, scientists tried to find the mechanism by which HHcy 
adversly affects the vessels. In recent years numerous in vitro and in vivo studies have gained 
new insights in the pathomechanisms of Hcy. One of these effects of Hcy is a reduction in the 
endothelial function. Endothelial cells synthesize several agents that are centrally involved in 
the regulation of vasoconstriction and vasodilation (Cooke JP., 2000). Endothelium-derived 
Disease Effect 
on Hcy 
Mechanism Reference 
Autoimmune diseases 
(rheumatoid arthritis) 
↑ - Drug use 
- Vitamin deficiency 
- Gastrointestinal dysfunction 
Roubenoff et al., 
1997 
Van Ede et al., 2001. 
Endocrine disorders 
- Early stage of diabetes 
 
 
- Late stage of diabetes 
 
 
- Hypothyroidism 
- Hyperthyroidism 
 
↓ 
 
 
↑ 
 
 
↑ 
↓ 
 
- Glomerular hyperfiltration. 
- The effects of insulin. 
 
-Nephropathy and impaired 
renal clearance.  
 
- Thyroid hormones influence 
the synthesis of flavin 
mononucleide(FAD).  
 
 
Wollesen et al., 1999 
Schneede et al., 2000. 
 
Audelin et al., 2001. 
 
 
Nedrebo et al., 1998. 
Diekman et al., 2001. 
Hustad et al., 2000. 
Gastrointestinal disorders 
(ulcerative colitis, Crohn`s 
disease,…..) 
↑ - Malabsorption of vit B12 
and folate 
 
Gregory et al., 2001. 
Schneede et al., 2000.
Gout ↑ -Altered tubular excretion 
-decreased glomerular 
filtration 
 
Istok et al., 1999. 
Hyperproliferating 
diseases (cancer, psoriasis) 
↑  -The rapidly dividing cells 
use the the methyl group of 
Meth and the one carbon 
unite of THF at the expense 
of increased tHcy levels. 
  
Refsum and Ueland, 
1990. 
 
Renal disease ↑ Decreased the remethylation 
of Hcy in the kidney 
 
Van Guldener et al., 
1999 
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vasoconstrictors are thromboxane A2, prostaglandin H2, and endothelin 1. The endothelium-
derived vasodilators are nitric oxide (NO) and prostacyclin (PGL2) (Shimokawa H., 1999). 
HHcy mediates the endothelial dysfunction by several mechanisms (figure 1. 4): 
 
• HHcy may reduce the bioactivity of endothelium-derived nitric oxide (NO): 
During HHcy, the reaction of NO with superoxide produces peroxynitrite (ONOO־), which 
is a potent oxidant. ONOO - causes activation of poly (ADP-ribose) polymerase (PARP) 
which is an important mediator of vascular dysfunction in disease (Mujumdar et al., 2001). 
Also, ONOO -  can oxidize tetrahydrobiopterin, a critical cofactor for NO synthase (eNOS), 
leading to a reduced activity of eNOS or an eNOS-uncoupling where the electrons are 
transported to molecular oxygen forming O2˙¯ rather than to L-arginine forming NO˙ 
(Laursen et al., 2001). More that, HHcy inhibits the activity of eNOS by increasing the 
levels of asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of NO 
synthases, leading to reduce the bioavilability of No  (Stuhlinger et al., 2001; Boger et al., 
2000). 
 
• Hcy increases oxidative stress and levels of reactive oxygen species (ROS):  
Elevated tHcy levels inhibit the expression or function of antioxidant enzymes such as 
extracellular superoxide dismutas (EC-SOD) by stimulating the degradation of endothelial 
heparan sulfate proteoglycan (Yamamoto et al., 2000). More that, Hcy increases the activity 
of vascular sources of O2˙¯  including xantine oxidase, cyclooxygenase, nitric oxide syntesis 
(NOS), and NAD(P)H oxidase (Bagi et al., 2002; Hanna et al., 2002; ungvari et al., 2002; 
Mohazzab et al., 1994).  
 
• HHcy  can upregulate components of the inflammatory cascade: 
Hcy activates nuclear factor- B (NF- B) and causes overexpression of cytokines (e.g. tumor 
necrosis factor-α (TNF- α) (Hunt and Tyagi, 2002; Wang and Siow, 2000) leading to 
inhibition of vasoconstriction and thereby impairment of endothelial function. Also, TNF- α 
increases the activity of NAD(P)H oxidase causing, consequently, increased superoxides 
levels seen in HHcy (Frey et al., 2002; Fichtlschere et al., 2001). 
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figure 1. 4. Changes within the vessel wall in response to HHcy. HHcy causes decreased 
activity of the transporter for L-arginine (CAT-1), increased expression of caveolin-1, 
reduced expression of eNOS that can be also inhibited by ADMA 
 
 
 
 
1. 7. Classification of pregnancy hypertension  
Hypertension in pregnancy is defined according to the International Society for the Study of 
Hypertension in Pregnancy (ISSHP) as a diastolic blood pressure of ≥ 90 mmHg measured on 
two consecutive occasions 4 hour apart, or a single reading of diastolic blood pressure of 110 
mmHg or above. Frequently, hypertension in pregnancy is accompanied by proteinuria, 
defined as an urinary protein loss of ≥ 300 mg in a 24 hour specimen (Higgins and de Swiet, 
2001).  
The American National High Blood Pressure Education Program Working Group on High 
Blood Pressure in Pregnancy (NHBPEP) suggested diagnostic criteria to discriminate among 
the different types of hypertension in pregnancy (Roberts et al., 2003; report of the NHBPEP 
21 
working group on high blood pressure in pregnancy, 2000). According to the NHBPEP 
criteria,  women with increased blood pressure are classified as a follows: 
- Chronic hypertension: the hypertension that is present before pregnancy or before the 
20th week of gestation, or that is diagnosed for the first time during the pregnancy and 
persists postpartum. 
- Gestational hypertension: onset of hypertension after the 20th week of gestation. The 
combination of gestational hypertension and proteinuria is named preeclampsia 
syndrome. Women who do not manifest proteinuria or other related findings are 
retrospectively divided into two subgroups: 
 Transient hypertension: hypertension resolves by 12 weeks postpartum.  
 Chronic hypertension: hypertension does not resolve by 12 weeks postpartum. 
- Preeclampsia superimposed upon chronic hypertension: the occurrence of preeclampsia 
in a woman with preexisting hypertension. 
- Preeclampsia: onset of hypertension in combination with proteinuria after the 20th week 
of gestation and the remission of these signs after the delivery (Lindheimer et al., 1999). 
Preeclampsia can be classified into a mild, a moderate and a severe form according to 
the associated symptoms (table 1. 2). Eclampsia is the most severe form of 
preeclampsia, and is characterized by the occurrence of generalized convulsions during 
pregnancy, labour, or within 7 days after the delivery in the absence of preexisting 
epilepsy or convulsive disorders. Postpartum seizures account for about 44 % of all 
seizures (Munro PT., 2000). The HELLP-syndrome (Hemolysis, Elevated Liver 
enzymes, and Low Platelet count) is the most lifethreatining complication of 
preeclampsia and eclampsia. Nearly 10 % of severe preeclamptic women and 30-50 % 
of eclamptic women sustain a HELLP-syndrome.  
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Table 1. 2. Classification of preeclampsia according to the ISSHP guidelines 
    Mild   Moderate  Severe 
Diastolic blood pressure 90-100 mmHg 100-110 mmHg > 110 mmHg 
Headaches   minimal  mild   marked, persistent 
Visual symptoms  minimal  mild   marked, persistent 
Blindness   absent   absent   present 
Convulsions   absent   absent   present 
Upper abdominal pain absent   absent   present 
Fetal growth retardation absent   absent   present 
Intravascular hemolysis absent   absent   present 
Thrombocytopenia (< 105 ) absent   absent   present 
Oliguria < 400 dL/24 hour absent   absent   present 
creatinine, uric acid levels normal   mildly elevated markedly elevated 
SGOT, SGPT, LDH  normal   mildly elevated markedly elevated 
SGOT: serum glutamic-oxaloacetic transaminase; SGPT: serum glutamic-pyruvic 
transaminase; LDH: lactate dehydrogenase 
 
 
 
 
1. 8. Incidence and Risk factors 
Hypertensive disorders occur in 12-22 % of all pregnancies. Preeclampsia is the most frequent 
hypertensive disorder during pregnancy. Worldwide, 3-14 % of all pregnancies are 
complicated by preeclampsia. In industrialized western country the frequency ranges between 
5-8 % (Sibai et al., 1995; Cunningham and Lindheime, 1992;  Saftlas et al., 1990). Three to 
five percent of all cases of preeclampsia occur during the first pregnancy. Between 5-10 % of 
these cases develop severe preeclampsia according to the ISSHP criteria. The maternal 
morbidity and mortality because of preeclampsia account for about 16 % of all maternal 
deaths in the UK. More than 40 % of iatrogenic premature deliveries are attributed to 
preeclampsia. The incidence of eclampsia is 0.2 % of all pregnancies and causes the 
termination of 1 in 1000 pregnancies. 
The developing of preeclampsia is related to several risk factors such as:  
- Nulliparity, primiparity (Skjaerven et al., 2002; Eskenaziet et al., 1991). 
- Previous preeclampsia and positive family history of preeclampsia (Nilsson et al., 2004; 
Saftlas et al., 1990). 
- Multiple (twin, triplet) pregnancies (Mastrobattista et al., 1997; Coonrod et al., 1995). 
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- Black race and age < 19 or > 35 years (Chesley LC., 1984). 
- Work-related factors (Klonoff et al., 1996). 
- Diseases such as hypertension (Sibai et al., 1995), renal disease (Rey and Couturier, 
1994), diabetes mellitus (Nilsson et al., 2004), and thrombophilic disorders are also 
associated with an increased risk for preeclampsia.  
Additionally, several studies suggested elevated tHcy levels as a relevant risk factor for 
preeclampsia.  
 
1. 9. Hcy in normal and pregnancy complicated with preeclampsia  
Preeclampsia is a leading cause of maternal mortality. Recently, it was proposed that 
preeclampsia is a two-stage disease. The first stage is characterized by reduction of placental 
perfusion. The second stage is dominated by the maternal syndrome: hypertension 
accompanied with proteinuria (Roberts and Cooper, 2001). Oxidative stress has been 
suggested as a major factor for the progression of the disease. Together with other maternal 
factors such as age, nulliparity, multiple pregnancies, etc., oxidative stress causes endothelial 
dysfunction, which is supposed as the underlying pathomechanism of preeclampsia (Var et 
al., 2003; Sikkema et al., 2001). Up to date, The etiology of preeclampsia is still not fully 
understood. However, its occurrence and progression depend on a complex pattern of 
interactions between genetic make-up and acquired factors (Roberts and Cooper, 2001).  
Pregnancy is associated with higher B vitamins requirements to respond well to the increased 
demands of maternal and growing infants. B vitamins (folate, vit B12, and B6) play as 
cofactors in numerous of metabolic reaction such as one carbon metabolism required for DNA 
and RNA synthase and cell division. Serum concentrations of these vitamins are commonly 
decline throughout pregnancy (Cikot et al., 2001). It is thought that this decline is related to 
higher metabolic rate and active transport of the vitamins into the placental tissues and the 
fetus. Maternal B-vitamins status from preconception throughout pregnancy strongly affects 
the infant status of these vitamins at birth (Murphy et al., 2004; Monsen et al., 2001). The 
influence of maternal B-vitamins status on the nutritional status of infants is even extended 
into the lactation (Allen LH., 2005; Black et al., 1994). For instance, in a breast milk sample 
collected from lactating Guatemalan women and their infants at 3 month, breast milk vitamin 
B-12 was low in 31 %, and 62 % of infants had low or deficient vit B12 concentration at age 7 
to 12 months (Casterline et al., 1997).  
Maternal nutritional status has received increasing attention as an important risk factor that 
influences the outcome and progress of pregnancy (Vollset et al., 2000; Ray et al., 1999). Low 
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maternal folate status has been associated with increased the risk of preterm delivery, low 
birth weight, and NTD (Scholl et al., 2000; Hibbard BM., 1964). Likewise, vit B12 deficiency 
has been associated with maternal megaloblastic anemia, and increased the risk of very early 
recurrent abortion, and NTD (Groenen et al., 2004; Savage et al., 1994). Therefore, prenatal 
vitamin supplementation has been recommended (Rolschau et al., 1999; Czeizel AE., 1993). 
In US,  folic acid-enriched products improved the maternal folate status and led to a 15–30 % 
decrease in neural tube defects. Additionally, a decrease in the incidence of preeclampsia and 
gestational hypertension in women with folate supplementation has been found (Hernandez-
Diaz et al., 2002; Sanchez et al., 2001).  
Elevated tHcy concentration is a proxy measure for deficiency of B-vitamins (folate, vit B12, 
and vit B6). Maternal HHcy was associated with serious pregnancy complication affecting 
adversely the mothers as well as their offsprings (Vollest et al., 2000). In a study included 93 
women and their offspring, Murphy et al. found that the fetal tHcy concentration and birth 
weight were significantly correlated to maternal tHcy from preconception throughout 
pregnancy. Additionally, mothers in the highest tHcy tertile at 8 wk gestation were three time 
more likely to give birth to a neonate in the lowest weight tertile. Neonates of mothers in the 
highest tHcy tertile at labor weighed 228 g less than those born to mothers in the two lowest 
tertile (Murphy et al., 2004). Several studies concerning the association between maternal 
HHcy and adverse outcome were reported (Cotter et al., 2003; Nelen et al., 2000; Van der 
Molen et al., 2000; Vollest et al., 2000; Goddijn et al., 1996; Rajkovic et al., 1997; Powers et 
al., 1998; Dekker et al., 1995; Steegers-Theunissen et al., 1995). 
Serum tHcy concentrations fall in normal pregnancy as early as 8-10 weeksۥ gestation 
(Murphy et al., 2002; Andersson et al., 1992). The lowest values of Hcy, approximately 50-60 
% of that found in non-pregnant women, have been found in the second trimester (Andersson 
et al., 1992; Kang et al., 1986). In the third trimester, Hcy increases towards its preconception 
values (Holmes et al., 2005; Lopez-Quesada et al., 2003). Nevertheless, Hcy concentration 
before delivery remains lower than that at preconception (Murphy et al., 2004). Several 
mechanisms have been proposed to explain the decrease in maternal tHcy, including the 
normal increase in the glomerular filtration rate that accompanies pregnancy, the increase in 
plasma volume and associated haemodilution, increased the uptake of maternal Hcy by the 
fetus, increased maternal B-vitamins intake, and the hormonal effect on Hcy metabolism 
(Murphy et al., 2002; walker et al., 1999; Bonnette et al., 1998; Malinow et al., 1998). 
However, the exact mechanism is still unclear, but one possible benefit outcome of lower Hcy 
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in pregnancy may be the protection of the mother and fetus from Hcy-dependent pregnancy 
complications (Holmes VA., 2003). 
HHcy adversely affects the vessels causing endothelial dysfunction and vascular damage 
(Geisel et al., 2003; Herrmann and Knapp, 2002; Stanger et al., 2001). Recently, HHcy has 
been closely related to preeclampsia, since endothelial dysfunction is one major complication 
in this disease (Powers et al., 2001; 1998; Roberts et al., 1989). A study in Netherland 
included women with a history of severe early-onset preeclampsia showed that the incidence 
of HHcy in these women were 18 % compared with an incidence of 2.5 % in normal 
population (Dekker et al., 1995). A study from African women showed an odds ratio for 
eclampsia of 6.03 among women in the highest quartile of the control Hcy distribution 
compared with women in the lowest quartile. The corresponding odds ratio for preeclampsia 
was 4.57 (Rajkovic et al., 1999). Another study included Peruvian women found that relative 
to women in the lower quartile of the control Hcy distribution, women who have tHcy 
concentration in the highest quartiles experienced a 2.9-fold increased risk of preeclampsia 
(Sanchez et al., 2001). The same group found that after adjustment for potential confounder, 
the relative risk of preeclampsia increased to 4-fold, suggesting that elevated maternal tHcy 
levels plays a significant role in the pathogenesis of preeclampsia. Several studies were 
initiated addressed Hcy as a biomarker with predictive value early in the pregnancy for 
identifying women at risk of subsequent development of preeclampsia (D'Anna et al., 2004; 
Cotter et al., 2001; Hietala et al., 2001; Hogg et al., 2000; Sorensen et al., 1999). 
Unfortunately, conflicting results were obtained.  
In preeclamptic women, elevated Hcy concentrations have been found throughout all 
pregnancy stages and postpartum (Lopez-Quesada et al., 2003; Cotter et al., 2001; Sanchez et 
al., 2001; Wang et al., 2000; Rajkovic et al., 1999; Sorensen et al., 1999; powers et al., 1998; 
Dekker et al., 1995). Furthermore, women with a history of preeclampsia also have elevated 
Hcy levels (Raijmakers et al., 2004; vollset et al., 2000). The reason behind tHcy elevation 
during preeclampsia is still not clear. However, several explanations have been suggested, 
including renal insufficiency (Brattstrom L., 2003), decreased the reformation of Meth from 
Hcy for fetal demand (Malinow et al., 1998), disturbance of the Hcy metabolism by the liver 
(Oosterhof et al., 1994), decrease in the whole body remethylation (Powers et al., 2004), 
reduction of B-vitamins occurred during preeclampsia (Park et al., 2004). However, there are 
also studies that did not find difference in maternal Hcy concentration between preeclamptic 
and normal pregnant women (D'Anna et al., 2004; Herrmann et al., 2004; Mayerhofer et al., 
2000) (table 1. 3). The discrepancy in the obtained results may be contributed, somewhat, to 
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the differences in the factors that determine Hcy concentration in the body and which were 
not measured together in most of these studies (i.e. vitamin status, genetic factors, lifestyle, 
renal function, diseases, drugs consumption, socioeconomic status, etc.). Folate was measured 
in only some studies. Although many publications reported no significant difference in folate 
levels between preeclamptic and control pregnants (Powers et al., 1998; Rajkovic et al., 
1997), recent studies found that lower folate levels were associated with a higher risk of 
preeclampsia (Sanchez et al., 2001; Rajkovic et al., 2000). The two existing studies measuring 
vit B12 in preeclamptic women did not observe an association between the risk for 
preeclampsia and low serum vit B12 concentration (Powers et al., 1998; Rajkovic et al., 
1997). The mutation of the MTHFR 677C→T has been postulated as a risk factor for 
preeclampsia. Many studies performed to investigate the impact of this mutation for the 
genesis of preeclampsia. Existing results are conflicting. Japanese and Italian pregnants with 
the C677T mutation have been found to be prone to preeclampsia (Grandone et al., 1997; 
Sohda et al., 1997), while Australian women are not (Kaiser et al., 2001; 2000). In a group of 
Americans, Powers et al. (2003) demonstrated that MTHFR mutation is not a risk factor for 
preeclampsia if prenatal folate is substituted. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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Table 1. 3. Summary of the existing studies about preeclampsia and Hcy 
Author/date Study 
groups 
Sampling Result 
D`Anna, 
2004 
PE= 27 
IUGR= 36 
Con=63  
In the early 
second 
trimester, and 
at delivery 
- No differences in Hcy between study groups in the 
early second trimester. 
- At delivery, preeclamptic women had significantly 
higher Hcy levels than controls. 
 
Herrmann, 
2004 
PE= 24 
HELLP=20 
Con= 34 
At 35 weeks 
of gestational 
age 
- Elevated Hcy levels are seen only in HELLP group 
compared with control group. 
- Folic acid, vit B6, and MMA were not different 
between the study groups. 
 
Patrick, 2004 Black 
PE= 26 
Con=52 
White 
PE= 34 
Con=48 
Third 
trimester 
- Folic acid concentrations were lower in black women 
compared with white women.  
- Black women with PE had elevated Hcy levels 
compared with black women with normal pregnancy, 
white women with preeclampsia, and white women 
with normal pregnancy 
  
Cotter, 2003 PE= 71 
Con= 142 
At 16 wk Women who developed nonsevere PE Had higher Hcy 
levels in early pregnancy. 
 
Lopez-
Quesada, 
2003 
PE= 32 
Con=64 
 
Third 
trimester 
Hcy and folate were significantly higher in PE 
compared with controls in the third trimester.  
Tug, 2003 PE= 20 
Con= 20 
Third 
trimester 
Preeclamptic women had elevated Hcy levels 
compared with normotensive control. 
 
Cotter, 2001 PE=56, 
Con=112 
Second 
trimester 
PE have elevated Hcy in early pregnancy compared 
with normal pregnancy 
 
Hietala, 2001 PE= 34 
Con= 68 
At 16 wk No differences in Hcy levels between women who 
developed PE or who remained normotensive. 
 
Power, 2001 PE= 17 
TH= 16 
Con= 34 
At delivery Hcy and cellular fibronectin were significantly higher 
in preeclamptic women compared to subjects from the 
other two group. 
 
Raijmakers, 
2001 
PE= 20 
Con= 10 
NP= 10 
 Con had Hcy levels lower than NP 
PE had higher Hcy levels than con 
Sanchez et 
al., 2001 
PE= 125 
Con= 179 
Third 
trimester 
Women in the highest quartile of Hcy and lowest 
quartile of folate experinced increased risk of PE, 
whereas no increased risk of PE associated with low 
plasma Vit B12 concentration. 
 
Hogg, 2000 PE= 4 
PIH= 12 
IUGR= 22 
Con= 
 - At 26 wk no significant differences in Hcy levels 
between PE, PIH, and Con 
- At 36, PE and PIH had higher Hcy compared with 
Con. 
 
Mayerhofer, 
2000 
 
 
PE=45 
Con=45 
Second and 
third trimester
No difference in Hcy levels between prerclampsia 
group and control group 
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Wang, 2000 PE=43 
Con=26 
Within one 
week befor 
delivery 
THcy was significantly higher in preeclampsia group 
compared with control group. 
Rajkovic, 
1999 
EC=33 
PE=138 
Con=185 
Postpartum The mean Hcy levels was significantly higher in 
women with PE and EC than in control group 
(P<ּ001).  
 
Sorensen, 
1999 
PE=52 
Con=56 
Second 
trimester 
Second trimester elevation of Hcy was associated 
with a 3.2- fold increase risk of preeclampsia. 
 
Powers, 
1998 
PE=21 
Con=33 
Antepartum Hcy, malondialdehyd, TG. Fibronectin are higher in 
PE than in Control (P<ּ04, P<ּ001, P<ּ001, P<ּ006 
respectively). 
 
Rajkovic, 
1997 
PE=20 
Con=20 
At the 
delivery 
 - PE had significantly higher tHcy than control group 
(P<ּ001) 
- Folic acid and vit B12 were not significantly 
different between the two groups. 
 
Dekker, 
1995 
PE=41 
EC=7 
HELLP=53 
 
Postpartum 17,7 % of women with a history of severe PE had a 
positive methionine loading test 
Con ═ Control group include normotensive pregnant women 
EC= Eclampsia 
HELLP= “Hemolysis, elevated liver enzyme, low platelet” syndrome 
MMA= Methylmalonic acid 
NP= Non-pregnant women   
PE= Preeclampsia 
TH= Transient hypertension 
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2. THE AIM OF THE STUDY 
 
The overall maternal and prenatal mortalities in Syria was estimated to be 4.3 % and 2.6 %, 
respectively. Recently, a case-control study on Syrian patients with coronary heart disease has 
shown a high prevalence of HHcy (Hcy > 12 µmol/L) and functional vit B12 deficiency, 
indicated by elevated MMA and low holoTC, in patients and, more importantly, in healthy 
subjects. Additionally, a more recent case-control study on Syrian young patients with a 
history of thrombosis has shown that low levels of folate or vit B12 were independently and 
strongly associated with the risk of venous thrombosis, and this risk was stronger than that 
introduced by elevated Hcy levels. The high prevalence of HHcy and B-vitamin deficiency in 
Syrian population was attributed to Syrian lifestyle. Elevated maternal tHcy concentrations 
and low B-vitamins status have been recently related to several pregnancy complications and 
adverse outcomes. Therefore, the high prevalence of HHcy and B-vitamins deficiency in 
Syria is a serious problem in this region where a high birth-rate is present.   
The current study was undertaken with the aim to investigate the role of low maternal B-
vitamin status and HHcy in complicated pregnancies in Syria. For this purpose maternal B 
vitamins concentrations, homocysteine, and other associated metabolites, including Cys, 
MMA, and holoTC, were measured in a group of Syrian preeclamptic women and 
normotensive pregnant women of the same socio-economic status using modern laboratory 
analyser. The direct measurement of serum B-vitamin does not well represent the functional 
supply with these vitamins, and the parallel measurement of the metabolites provides a more 
sensitive and specific approach for identifying B vitamins status at the cellular levels. 
MTHFR C677T mutation is associated with decreased enzyme activity and may therefore 
provoke HHcy in the presence of low folate status. Recently, MTHFR TT has been postulated 
as a risk factor for preeclampsia. Therefore, the MTHFR genotype was investigated in this 
study. 
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3. MATERIALS AND METHODS 
 
Subjects and study design 
Two hundred and seventy five nulliparous, uni and multi parous women at the second and the 
third trimester of their pregnancy were included in this study. Subjects were divided into two 
groups: women with a normal pregnancy (n = 98), women with pregnancy complicated with 
preeclampsia and eclampsia (n = 177). Subjects have been recruited between July 2002-2003 
at the department of obstetrics and gynecology of the university of Damascus, Syria New 
Maternal Hospital. According to the ISSHP guidelines, preeclampsia (PE) was diagnosed 
when hypertension and proteinuria occurred after 20 weeks of gestation and disappeared 
spontaneously after the delivery, and eclampsia (EC) was defined as hypertension and 
proteinuria in combination with seizures not related to other diseases. Hypertension was 
defined as a diastolic blood pressure of ≥ 90 mmHg in two consecutive occasions 6 hour (h) 
apart. Proteinuria was defined when urine protein concentration exceeded 300 mg per 24 h or 
“+2” in a dipstick test in two random specimens collected at least 6 h apart. Eligible controls 
were subjects without hypertension and proteinuria throughout the entire  pregnancy. Neither 
patients nor controls had chronic hypertension, renal or metabolic disease, platelet disorders, 
autoimmune disorders or epilepsy. All subjects filled in a questionnaire to register 
anthropometric, reproductive, and lifestyle characteristics (smoking, coffee consumption, diet, 
physical activity, vitamins use)(table 4. 1). Gestational age was calculated considering the 
first day of the last menstrual period as day 0. A major problem was the registration of 
maternal weight and blood pressure before the pregnancy since most women did not have 
routine medical pre-pregnancy care. Two formal approval were obtained to perform this study 
from the ministry of health and the board of hospital of the university of Damasccus. 
Informed consent was obtained from all participants. 
 
Preanalytical sample handling 
Fasting venous blood samples were drawn after 12 h of fasting from the antecubital vein using 
ethylenediamine tetraacetic acid (EDTA) containing Vacutainer® tubes and dry Vacutainer® 
tubes (BD, Germany). EDTA-sample were used for whole blood and plasma analyses. Blood 
samples collected into dry Vacutainer® tubes were used for serum preparation. Blood 
sampling was done immediately after the diagnosis of preeclampsia. Therefore, the day of 
blood sampling throughout the pregnancy was not standardized. However, in all cases one 
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blood sample was taken within 8 h before the delivery. The blood was allowed to clot on ice. 
Plasma and serum were separated within 40 minutes (min) after sample collection by 
centrifugation at 2000 × g for 20 min. Several aliquots of plasma and serum were prepared 
and stored at – 80 ºC for further analysis. After removal of EDTA-plasma the remaining cells 
of the patients group were used to extract genomic DNA by a manual isolation protocol (see 
below). Genomic DNA of the controls was extracted from frozen whole blood using a 
commercial kit (QIAamp® DNA Mini Kit; Qiagen, Germany). 
 
Laboratory analysis  
Serum concentrations of blood glucose, creatinine, uric acid, urea, total-bilirubin, alanin 
aminotransferase (GPT), aspartat aminotransferase (GOT), cholesterol (Cho), triglyceride 
(TG), and high-density lipoprotein (HLD) were measured on a Hitachi 917 automated 
analyzer using commercial assays from Roche diagnostic, Germany (table 3. 3). Moreover, 
tHcy, Cys, MMA, vit B6, vit B12, and folate have been determined. The C677T MTHFR 
polymorphism was genotyped using a polymerase chain reaction/restriction fragment length 
polymorphism method. The methods used are listed in (table 3. 1). 
  
Table 3. 1. Overview about the main outcome measures  
Parameter  Method equipment,manufacturer  Reference range 
Hcy GC-MS   Agilent, USA   <12 µmol/L.  
Cys GC-MS   Agilent, USA   65-301 nmol/L. 
MMA GC-MS   Agilent, USA   73-271 nmol/L. 
  
Vit-B6 HPLC   Bio-Rad, Germany  4.8-36.9 ng/ml. 
 
Vit-B12 Chemiluminescence  Bayer, Germany  156-674 pmol/L. 
Folate Chemiluminescence Bayer, Germany  5-14.6 ng/ml. 
 
HoloTC Radioimmunoassay Axis-Shield, Norway  ≥ 35 pmol/L.   
 
Routin Hitachi analyser  Roche, Germany 
Parameters  
 
MTHFR mutation PCR-based RFLP Qiagen, Germany 
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 3. 1. Analytes detected by GC-MS (Hcy, Cys, MMA) 
Serum tHcy, Cys, and MMA were separated by gas chromatography (GC) and quantified by 
mass spectrometry (MS). In general, separation and quantification of a mixture of compounds 
by GC-MS is based on the relative affinity of each component to the stationary phase of the 
GC, over which the mobile phase continuously flows. Compounds with a low affinity will 
elute earlier from the column than those with a high affinity. Since gas chromatography 
requires analytes in a volatile form, the sample were converted into a gaseous form using the 
method described by Stabler et al. (1993) and Allen et al. (1993).  
The mass spectrometer provides the mass spectrum representing the abundance of ions of a 
given mass (abundance, Y axis) versus the mass to charge ratio of these ions (m/z, X axis). 
The effluent of the GC enters the mass spectrometer system through the interface. In the ion 
source the mass is ionised by electrons and undergoes fragmentation. Then, a quadrupole or a 
mass filter separates the ions that appear at the same time according to their mass. Finally, the 
detector collects and measure the received ions. The displayed peaks are proportional to the 
total number of ions of each mass (figure 3. 1). Deuterated Hcy, Cys, and MMA were added 
to the samples as an internal standard. The usage of an internal standard represents an easy 
way to calculate the concentration of a distinct parameter independently from the recovery 
that may differ from one sample to the other. 
The concentrations of Hcy, Cys, and MMA were determined by dividing the integrated area 
of the endogenous substances by the integrated area of the deuterated internal standard. The 
results were multiplied with a factor which is the equivalent amount of deuterated internal 
standard that was added to each sample. The formula is:  
 
 
 
 
 
 
   
 
    As: factor = 39.2 µmol/L, 1000 nmol/L, 4087.5 nmol/L for Hcy, Cys, and 
MMA, respectively. 
 
 
 
Concentration  = 
  
Area of the endogenous parameter × concentration of the internal  standard  
Area of the internal standard
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 Abundance 
                                                                                    
 
 
 
 
 
 
 
 
   M/Z 
 
 Figure 3. 1. Illustrate the mass spectrum which is a plot of the number of ions as a 
function of mass to charge ratio (m/z) 
 
 
 
 
In this study, the mass selective detector operated in the ion monitoring mode in which the 
ions mass/charge (M/Z) 420.2, 362, 289 were monitored for endogenous Hcy, Cys, and MMA 
respectively. The ions M/Z 424.2, 366, 292 were monitored for deuterated Hcy, Cys, and 
MMA, respectively. The GC column operated with the following conditions: 
Flow   1.0 ml/min  Initial temperature  80 ˚C 
Film thickness 0.25 µm  Final temperature  310 ˚C  
Length   30 m   Temperature limits  60 ˚C to 325 ˚C 
Phase ratio  250   Rate of temperature increase 30 ˚C/min 
Head pressure  53.3 psi 
 
3. 1. 1. Determination of tHcy and Cys 
Hcy and Cys were quantified in the same (400 µl) sample. In one run, 20 to 22 samples and 
two pool sera were analysed. In the following, the detailed sample preparation is described: 
1. In a 10 ml plastic tube, were added: 
▪ 1 mL water for chromatography (Merck, Germany) 
▪ 400 µL serum sample (patient or pool) 
▪ 50 µL of deuterated Cys (concentration = 83 × 10-4 mol/L) (CDN Isotopes, Canada) 
▪ 20 µl of deuterated Hcy (concentration = 784 × 10-3 mol/L) (CDN Isotopes, Canada) 
Mass spectrum of the endogenous parameter 
Mass spectrum of the internal standard 
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▪ 30 µl of a freshly prepared Dithiothreitol (DTT) (Carl Roth GmbH, Germany) as a 
reducing agent (10 mg DTT in 1 ml NaOH (1 N)) 
2. This mixture was incubated at 42 ˚C for 30 min to allow reduction of disulfides of 
homocystine to Hcy 
3. The mixture was applied to a disposable column (Bio-RAD, Germany) containing 100 mg 
(dry weight) of an anion exchange resin (Bio-RAD, Germany) that had previously been 
washed once with 1 ml of methanol and once with 3.3 ml water 
4. The column was washed three times with 3 ml water and once with 3 ml of methanol 
5. Hcy and Cys were eluted into a vial using 1.1 ml of 0.4 N acetic acid in methanol 
6. The elutes were dried by vacuum centrifugation at 45 ˚C using a concentrator (Eppendorf, 
Germany) 
7. The dried elutes were converted into a volatile derivative by adding 20 µl Acetonitril 
(Merck, Germany) and 10 µl N-methyl-N (tert-butyldimethylsilyl) rifluoracetamide 
(MTBDSFA) (Machery and Nagel, Germany). Subsequently, samples were incubated for 
5 min in a microwave by 440 Watt and put into the GC-MS analyser (Hewlett-packard, 
USA). Finally, 1 µL was injected for analysis. 
Deuterated and endogenous Hcy were eluted at approximately 13.3 min (retention time). The 
retention time of the deuterated and endogenous Cys was ≈ 17.1 min. In normal population, 
the cut-off value for Hcy is 12 µmol/L, and Cys has a reference interval of 65-301 nmol/L. 
 
3. 1. 2. Determination of MMA 
In one run, 20 to 22 samples and two pool sera were analysed. The sample preparation for the 
quantification of MMA was as follows: 
1. In 10 ml plastic tube, were added: 
▪ 1 mL water for chromatography  
▪ 400 µL serum sample (patient or pool) 
▪ 50 µL of deuterated MMA (concentration = 1635 × 10-7 mol/L) (CDN Isotopes, 
Canada)  
2. This mixture was transferred to a previously activated anion exchange Resin 
3. The column was washed once with 3 ml water, and three times with 3 ml of acetic acid in 
methanol (0.01 N) 
4. The sample was eluted into a vial using 1.1 ml of 4 N acetic acid in (1 N) HCL. The elutes 
were dried and derivatized using the same protocol as for Hcy and Cys (see above) 
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The retention time of MMA and MMA internal standard was 17.1 min. The expected values 
of MMA in healthy people are between 73-271 nmol/L. 
A serum pool was used for internal quality control. The within-day coefficients of variation 
(CV) for Hcy, Cys, and MMA were 4.9 %, 1.3 %, and 5.1 %, respectively. The interassy 
CV`s  were 4.9 % for Hcy, 3.9 % for Cys, and 4.8 % for MMA. 
 
 
Table 3. 2. Summarization of the sample preparation for the metabolites determined by GC-
MS 
 Hcy Cys MMA 
Before applying the sample to the column    
Water 1 ml 1 ml 1 ml 
Hcy internal standard  20 µl - - 
Cys internal standard - 50 µl - 
MMA internal standard -  - 50 µl 
Reducing agent (DTT) 30 µl - - 
Incubation at 42 ºC  30 min - - 
After applying the sample to the column    
First wash (water) 3 x with 3 ml 3 x with 3 ml 1 x with 3 ml 
Second wash 1 x with 3 ml 
meth 
1 x with 3 ml 
meth 
3 x with 
(0.01N) 
Aa+meth 
Elution from the column 0.4 N 
(Aa+meth) 
0.4 N 
(Aa+meth) 
4 N (Aa+HCl) 
Drying of the elutes by vacuum centrifuge 
at 45  ºC 
 
   
Derivatization of elutes with derivatizing 
agent (An + MTBDSFA) 
 
   
Application of the samples to the GC-MS 
analyser. 
   
Abbreviations: 
Aa: acetic acid, An: Acetonitril; Cys: cystathionine; DTT: 1,4-dithiothreitol; Hcy: 
homocysteine; meth: methanol; MMA: methylmalonic acide; MTBDSFA: N-methyl-N (tert-
butyldimethylsilyl) trifluoracetamide. 
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Preparation of the anion exchange resin 
The anionic exchange resin was washed by an equivalent amount of HCl (1 N). After removal 
of HCL, the resin was washed again by an equivalent amount of methanol. Then, the resin 
was left to dry in an oven at 60 ºC for three to five hours or over night at 37 ºC. Before sample 
application, 100 mg of dry ion exchange resin were put into a disposable column and washed 
with different solutions before application of the samples as described in the methods above. 
 
Solution used in GC-MS  methods:     
• 4 N acetic acid stock solution: 
24 ml acetic acid + 76 ml methanol for chromatography 
• 0.4 N acetic acid (used for elution Hcy and Cys) 
10 ml acetic acid (4 N) + 90 ml methanol for chromatography 
• 0.01 N acetic acid (the column`s washing solution for MMA measurement) 
12.5 ml acetic acid (0.4 N) + 487.5 ml methanol for chromatography 
• Solution for MMA elution  
90 ml acetic acid (4 N) + 10 ml HCL (1 N) 
 
Technical specifications of the GC-MS  system  
The GC-MS system was provided by Hewlett-Packard, USA.  
The GC-column contained HP-5 MS (crosslinked 5 % phenyl methyl siloxane) as a stationary 
phase (Model No: Hp 19091S-433) was provided by Agilent technologies®, USA. 
Capillary gas chromatograph  model 6890 
Autosampler    model 7774  
Mass-selective detector  model 5973 
The system was controlled via the MS DOS chemstation (Agilent technologies®, USA). 
0 
0 
0 
0 
0 
0 
0 
0 
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3. 2. Determination of Vit B6 
In this study, pyridoxal-5-phosphate (PLP), the active form of vit B6, was measured by 
reversed phase high performance liquid chromatography (HPLC) with fluorescence detection 
using a commercial kit from Immundiagnostik (Germany). In vivo, vit B6 can be found in 
three forms: pyridoxine, pyridoxal, and pyridoxamin. 
HPLC is based on different affinities of the sample compounds for the mobile and stationary 
phase. Comparable to GC, the HPLC system consisted of a mobile phase reservoir, a pump 
for transporting the mobile phase through the system, an injector for sample application into 
the column, the chromatography column, a fluorescence detector, and a computer. Reversed-
phase chromatography is characterized by elution of the sample compounds with a mobile 
phase that is significantly more polar than the stationary phase. Vit B6 eluted after ~3 min. 
For the calculation of vit B6 concentration a calibrator with a known vit B6 concentration was 
included in each run. Vit B6 concentration was then calculated by the following formular: 
 
 
The detection limit was 0.2 ng/ml with persistent linearity up to 250 ng/ml. The detailed test 
protocol is listed below: 
High molecular substances were precipitated by adding precipitating reagent to the samples. 
After removal of the supernatant, vit B6 was derivatized by incubation of the sample at 60 ˚C 
for 20 min with derivatizing reagent. Then, samples were placed onto the HPLC system. After 
injection, samples passed the column and were subsequently eluted by isocratic elution, in 
which the composition of the mobile phase remains constant during the elution process.  
In each run one calibrator (one point calibration), two controls (high and low), and 21 samples 
were analysed. Sample preparation was as follows:  
-  In a micro centrifuge tube (Eppendorf, Germany) were added: 
▪ 200 µl serum sample, calibrator, or control 
▪ 50 µl precipitating reagent® (Immundiagnostik, Germany) 
-  The mixture was mixed vigorously to remove the high molecular substances and incubated 
at + 4 ˚C for 10 min 
Vitamin B6  =
Peak height of patient × calibrator conc. (ng/ml)
Peak height of calibrator
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-  After centrifugation for 5 min at 20000 g (Hettich centrifugator EBA 12, Germany), 100 µl 
of supernatant were transferred to a 1.5 ml plastic cup, and 250 µL derivatisation solution® 
(Immundiagnostik, Germany) were added 
-  The tube was incubated for 20 min in a water bath at 60 ˚C 
-  Prior to injection, this mixture was cooled at 2-8 ˚C for 10 min and centrifuged for 5 min at 
20000 g 
- 200 µl of the supernatant were transferred to a sealed auto sampler vial, and 20 µl were 
injected for analysis. 
 
Chromatographic conditions and materials 
Column material:  prontosil Eurobond C 185.0 µm (Immunodiagnostik,Germany) 
Column dimension:  125 mm × 4 mm 
Flow rate:   1-1.5 ml/min/temperature: 25 
Wavelength of detection Excitation 320 nm 
Emission 415 nm 
Injection volume:  20 µl  
Running time:   10 min 
The HPLC-system was provided by Agilent, (Bio-RAD, Germany). 
Mobile phase, calibrators, and controls were provided by Immunodiagnostik, Germany. 
The CV΄s for high (23.45 ng/ml) and low (8.25 ng/ml) controls were 5.22 % and 5.68 %, 
respectively. The normal range of the Vit B6 concentration is 4.3 – 17.9 ng/ml. 
 
3. 3. Determination of folic acid and vit B12 in serum 
Folate and vit B12 were measured on an ADVIA centaur automated analyzer (Bayer 
Diagnostics, Germany) using commercial assays from Bayer Diagnostics. Both assays are 
competitive chemiluminescence immunoassay. The principle of these assays is a competition 
of endogenous folate and vit B12 with acridinium ester-labeled folate and vit B12, 
respectively, for a limited number of binding sites on a solid phase. The solid phase consists 
of biotin-labeled folate binding protein and purified intrinsic factor, respectively. Both 
proteins are covalently coupled to paramagnetic particles in the solid phase. Prior to the 
incubation with acridinium ester-folate and vit B12, samples are treated with DTT to release 
folate and vit B12 from endogenous binding proteins. After binding of endogenous folate and 
vit B12, the unbound folate and vit B12 are washed away. Then, the chemiluminescence 
reaction is initiated by adding acid and base reagents. The concentrations of folate and vit B12 
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are inversely related to the relative light units (RLUs) detected by the system. Low and high 
controls were used for quality control. The CV΄s for vit B12 were 3.56 % and 4.47 % at 1201 
and 613 pg/ml, and for folate were 8.24 % and 7.94 % at 8.87 and 4.63 ng/ml. 
 
3. 4. Analysis of MTHFR-polymorphism 
MTHFR-polymorphism was analyzed by a polymerase chain reaction/restriction fragment 
length polymorphism (PCR/RfLP) method as previously described by (Frosst et al., 1995). 
The PCR product was digested with the restriction enzyme Hinf Ι (MBI, Germany) and then 
plotted by gel electrophoresis. 
 
3. 4. 1. DNA isolation 
● Manual isolation 
- 10 ml EDTA-blood and 40 ml blood lysis buffer (BLB) (1 x) were mixed in a 50 ml 
tube (BD, Germany), and placed on ice for 30 min 
- The tube was centrifuged for 10 min at + 4 ˚C with 2500 g. Then, the supernatant was 
removed, and the remaining leucocytes (pellet) were washed with BLB three times 
- The remaining white leucocyte layer were resuspended in 0.5 ml BLB 
- Then, 4 ml white lysis buffer (WLB), 200 µl Proteinase K, and 200 µl of 20 % sodium 
dodecyl sulphate (SDS, 20 % g/v) were added and the all suspension were incubated in 
a water-bath at + 37 ˚C for, at least, 12 h 
- The next day, 1.5 ml of 6 M sodium chlorid (NaCl) was added. After mixing for 15 
seconds (s), the suspension was centrifuged for 15 min at + 4 ˚C with 3000 g 
- The supernatant containing the soluble DNA was transferred into a sterile 50 ml tube 
and filled up with 2.5 times volume of absolute ethanol 
- The tube was shaked gently until the DNA appeared 
- Then, the DNA containing tube was centrifuged for 1-2 min with 6000 g, and the 
supernatant was discarded 
- The obtained DNA was washed from salts using 1 ml of ethanol 70 %. The washing 
procedure was repeated five times to remove any trace of the salts 
- Finally the DNA was resuspended in 0.5 ml tris-EDTA-buffer (TE-buffer) and 
incubated in a water-bath for one h at 60 ˚C 
The DNA was stored at + 4 ˚C until analysis. 
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Composition of solutions used for manual isolation 
BLB (20 x)        
- 3.1 M ammonium chloride (Merck)    MW = 53.49 g 
- 0.2 M potassium bicarbonate (Merck)   MW = 100.1 g 
- 20 mM EDTA (pH = 8) (Merck)    MW = 372.24 g/mol 
Adjust PH to 7.4 and fill up to 1000 ml with sterile water. Prior to use dilute 20x with sterile 
water. 
 
WLB (1 x)    
- 10 mM Tris (hydroxymethyle)- aminomethan (Merck) MW = 121.14 g/mol. 
- 400 mM Nacl (Merck)      MW = 58.44 g/mol. 
- 2 mM EDTA (pH = 8)       MW = 372.24 g/mol 
fill up to 1000 ml with sterile water.  
 
TE- buffer    . 
- 10 mM Tris  (hydroxymethyle)- aminomethan)  MW = 121.14 g/mol  
- 0.1 mM EDTA (PH = 8)     MW = 372.24 g/mol 
Adjust PH to 7.5 and fill up to 200 ml with sterile water  
 
Proteinase K  
20 mg Protinase K (Merck) 
Add sterile water until 1 ml. Aliquot the solution and store it at -20 ºC. 
 
SDS (20 % g/v) 
20 g SDS (Merck)       MW = 288.38 g/mol 
Add sterile water until 100 ml. Leave the solution at room temperature. 
 
NaCl (6 M) 
175.2 g Nacl         MW = 58.44 g/mol 
Add sterile water until 500 ml 
 
Ethanol 70 % 
70 ml ethanol absolute (Merck) 
30 ml sterile water 
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Ethanol absolute 
The ready to be used solution is stored at – 20 ºC. 
 
● Quick isolation 
Quick isolation was done using the commercially available QIAamp® DNA Mini Kit, which 
is based on the adsorption of DNA onto a silica-gel membrane after lysis with “Qiagen agent” 
and Proteinase K in the presence of a high salt concentration and ethanol (96-100 %). The 
procedure was as follows: 
- In a 1.5 ml tube, 200 µl blood, 200 µl AL® buffer, and 20 µl Proteinase K were added   
- After well mixing, the suspension was incubated at 56 ºC for 10 min (for cells lysis 
and proteolysis) 
- Two hundred microliter ethanol (96-100 %) were added 
- The mixture was applied to a QIAamp spin column (provided with the kit) and 
centrifuged at 6000 g for 1 min. Then, the filtrate was removed 
- The column was washed with 500 µl AW1® buffer and centrifuged at 6000 g for 1 
min. Then, the filtrate was removed again 
- The column was washed again with 500 µl AW2® buffer and centrifuged at 6000 g for 
3 min 
- The QIAamp spin column was placed in a clean 1.5 ml tube and 200 µl AE® buffer 
were added to elute the DNA. After incubation for 1 min at room temperature the 
column was centrifuged at 6000 g for 1 min. The filtrate contained the isolated DNA 
can be stored for long time at + 4 ºC. 
 
3. 4. 2. PCR /RFLS 
The principle of PCR is the synthesis of multiple replicates of a target DNA sequence. In this 
study, the replicates were then used to detect changes in the base sequence by RFLS. RFLS is 
a method using a cleavage enzyme (restriction enzyme) to fragment the PCR product at a 
defined point. If this point is mutated, the restriction enzyme can not cleave. The fragments 
are then analysed by gel electrophoresis. The PCR consists of 3 steps forming one cycle: 
denaturation, annealing, and elongation. To obtain sufficient amounts of the PCR product, 
multiple cycles have to be performed. Each step requires a different temperature and the 
instrument that takes samples through these cycles is known as thermocyclers. The MTHFR 
PCR was carried out in a total volume of 15 µl and contained the following ingredients: 
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- Nucleotides tri-phosphat (NTP- mix 2.5 mM) (Promega, Germany)  1.50 µl 
- Exonic primer (10 pmol/µl) (GibcoBRL, Eggenstein)    1.20 µl 
- Intronic primer (10 pmol/µl) (GibcoBRL, Eggenstein)   1.20 µl 
- Tag polymerase (Roche, Mannheim)      0.45 µl 
- PCR buffer (10 x + Mg Cl) (Roche, Mannheim)     1.50 µl 
- PCR-water (Eppendorf, Hamburg)      7.65 µl 
- DNA (sample)         1.50 µl 
 
The primers for analysis of the A→V change generate a fragment of 198 bp. The primers are:  
- Exonic primer  5َ- TGA AGG AGA AGG TGT CTG CGG GA- 3َ 
- Intronic primer 5َ- AGG ACG GTG CGG TGA GAG TG-3َ 
 
The PCR parameters were as follows:  
1. Initial denaturation at 94 ºC for 1 min  
2. 36 cycles denaturation at 94 ºC for 60 s, annealing at 60 ºC for 45 s, and extension at 
72 ºC for 30 s.  
3. Final extension for 10 min at 72 ºC to ensure complete extension of all PCR products.  
The amplified fragments were digested with the restriction enzyme HinfI (MBI, Germany) for 
three hours at 37 ºC. The mix consisted of 12.5 µl of amplified DNA, 1 µl of restriction 
enzyme HinfI and 1.4 µl enzyme buffer. The restriction enzyme will recognize the sequence 
5′ G↓ANTC 3′ in the two DNA strand and will divide the 198 bp PCR product into a 23 bp 
and a 175 bp fragments. The fragments were then detected using the horizontal slab gel 
electrophoresis. 
 
3. 4. 3. Gel electrophoresis 
DNA-fragments were applied on a 3 % (g/v) agaroase/NuSieve® GTG® Agarose gel (BMA, 
USA): 
Three grams agarose powder were cooked with 100 ml 1 × Tris-Borate-EDTA (TBE buffer) 
(GibcoBRL, Eggenstein) until the agarose was totally dissolved 
- The solution was cooled to 60 ºC. Then, 12 µl of ethidium bromide (Carl Roth GmbH, 
Germany) were added (from a stock solution of 10 mg/ml in water) 
- This agarose solution was poured on a plastic plate that had previously been equipped 
with a comb to form the wells. The gel was left for 30 min at room temperature for 
hardening 
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- The comb was removed and the gel was transferred to an electrophoresis tank (Biotec 
Fischer, Reiskirchen) that was filled with sufficient amount of electrophoresis buffer 
(1 x TBE). 
- Each well was filled with 16.5 µl of the DNA mix or DNA-standard (GibcoBRL, 
Eggenstein) of a known size (1 Kb). A voltage of 125 V for ~ 45 min was applied to 
allow the DNA fragments to migrate from the starting point into the body of the gel  
- Finally, the gel was tested by ultraviolet light and a photo for the gel was taken. 
The marker was used to determine the sizes of unknown DNAs if any systematic 
change of the gel happens during electrophoresis.  
 
The different genotypes are characterized by the following bands:   
- MTHFR-677 CC (wildtype): one band with 198 bp 
- MTHFR-677 CT (heterozygotes): one band with 198 bp + one band with 175 bp. 
- MTHFR-677 TT (homozygotes): one band with 175 bp. 
 
● The DNA-standard consisted of 1000 bp (1 kb), and was used at 66 ng/µL. The marker was 
prepared from a (1 µg/µL) stock solution as follows: 
Sixty-six microliters of stock solution were mixed with 230 µL of loading dye solution, 10 
µl of 1 M Tris buffer, and 10 µl of 2 M NaCl. Then, sterile water was added till 1 ml. 
 
● Ten ml of stop mix contained 1.0 ml bromphenol blue (Merck, Darmstadt), 2.5 mL xylene 
cyanol (Merck, Germany), 2 ml 50 mM EDTA, 2.38 ml glycerine (> 99.5 % purity), and 
2.1 ml sterile water. 
 
3. 5. RIA-Methods (holotranscobalamin-П (HoloTc- П) 
 HoloTC- П was assayed using a commercial RIA kit (Axis-Shield, Norway). This kit is based 
on the method described by Ueland et al. (2002). Briefly, total transcobalamin (TC) was first 
isolated from the serum sample or calibrator by incubating the serum with magnetic 
microspheres coated with monoclonal anti-human TC antibodies (capturing reagent). The vit 
B12 content of the sequestered holoTC was dissociated from TC by adding a DTT in 
phosphate buffer (reducing reagent) and denaturing reagent (extractant). At the same time, the 
released vit B12 was converted to the stable cyano form with potassium cyanide and 
quantified in a competitive binding assay. The 57C labelled vit B12 (tracer) competed with the 
cyano form of vit B12 for a specific number of binding sites of immobilized Intrinsic factor 
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(IF). After 1 h incubation, the unbound tracer was removed by centrifugation and the pellet 
was counted in a gamma counter. The concentration of vit B12 in the sample was inversely 
correlated to the measured radioactivity and determined by interpolation from a calibration 
curve that was constructed using holoTC calibrators of known concentrations (0, 10, 20, 40, 
80, and 160 pmol/L). Quality control sera were applied by the manufacturer of the kit. The 
CV´s for high and low controls were 9 % and 12 %, respectively. 
The expected values in healthy individuals are 35-171 pmol/L. 
 
3. 6. Clinical chemical parameter 
The following analytes were measured on a Hitachi 911 automated analyser using commercial 
assays (Roche Diagnostic, Germany): ALT, AST, total-bilirubin, creatinine, cholesterol, 
glucose, HDL-C plus, urea, uric acid. The methods are shortly described in table 3. 3. 
 
Table 3. 3. The routine chemistry of the study groups 
Parameter Principle Reference range 
ALT (GPT) 
 
ALT catalyzes the transamination of L-alanine to α-
ketoglutarate forming pyruvate and L-glutamate. The 
increase in pyruvate is determined in an reaction 
catalysed by lactate dehydrogenase accompanying with 
simultaneous oxidation of reduced NADH to NAD. 
The rate of photometrically determined NADH 
decrease is directly proportional to the rate of 
formation of pyruvate and thus the ALT activity 
 
Men: up to 41 U/L 
Female: up to 31U/L 
AST (GOT) AST catalyzes the transamination of L-aspartate to 2-
oxoglutarate forming L-glutamate and Oxalacetate. The 
Oxaloacetate formed is reduced to malate by malate 
dehydrogenase with simultaneous oxidation of reduced 
NADH to NAD. The change in absorbance with time 
(due to the conversion of NADH to NAD) is directly 
proportional to AST activity. 
 
Men: up to 37 U/L 
Female: up to 31U/L 
 
Bilirubin 
 
In strong acid solution containing 2,5-dichlorophenol 
diazonium salt, total bilirubin couples to form 
azobilirubin(red azo dye) that is directly proportional to 
the total bilirubin and determined photometrically. 
 
Adults: up to 1 mg/dl 
Creatinine 
 
In alkaline solution, creatinine forms a yellow orange 
complex with picrate. The color intensity is directly 
proportional to the creatinine concentration and can be 
measured photometrically. 
Male: 0.70-1.20 mg/dl
Female:0.50-0.90 mg/dl 
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Cholesterol 
 
Cholesterol ester is hydrolyse to cholesterol by the 
action of cholesterol esterase. The cholesterol is 
oxidized to a keton (cholest-4-en-3-one) by cholesterol 
oxidase and forms, simultaneously, H2O2 that is yield a 
dye by reaction of peroxidase. The colour intensity, 
which measured photometrically, is proportional to the 
concentration of cholesterol. 
 
Adults: < 200 mg/dl 
Glucose G-6-P dehydrogenase oxidizes G-6-P in the presence of 
NADP to gluconate-6-P. The amount of NADPH 
produced is directly proportional to the amount of 
glucose in the sample and is measured by absorbance at 
340 nm. 
 
Male: 0.70-1.20 mg/dl
Female:0.50-0.90 mg/d 
HDL-C plus 
 
The cholesterol esterase linked to polyethylene glycol 
(PEG) breaks the cholesterol ester of HDL-cholesterol 
into free cholesterol and fatty acids. The cholesterol is 
then oxidized by PEG-linked cholesterol oxidase to ∆4 
-cholestenone and H2O2. In the presence of Peroxidase 
and other reagents, H2O2 forms a blue dye that is 
measured by photometer.  
 
Male: 35-55 mg/dl 
Female: 45-65 mg/dl 
Urea 
 
Urea is hydrolysed by Urease to form CO2 and 
ammonia. The ammonia formed then reacts with α-
ketoglutarate and NADH in the presence of GLDH to 
yield glutamate and NAD+ the decrease in absorbance 
due to consumption of NADH is measured kinetically. 
 
10-50 mg/dl 
 
Uric acid 
 
The measurement depends on an enzymatic assay 
(uricase cleaves uric acid to form allantion). This 
enzymatic assay involves a Peroxidase system coupled 
with oxygen acceptors (4- aminophenazone) to produce 
a chromogen in the visible spectrum. 
 
Male: 3.4-7 mg/dl 
Female: 2.4-5.7 mg/dl 
 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
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3. 7. Material and instruments 
Materials 
- Acetic acid       Merck, Germany. 
 
- Acetonitrile      Merck, Germany 
 
- Agarose (NuSieve GTG)    BMA, USA. 
 
- AG MP-1M Ion Exchange Resin   Bio – RAD, Germany.   
    Microporous Anion Resin      
    (100 – 200 Mesh) chloride form. 
 
- Ammonium chloride    Merck, Germany. 
 
- calibrator and controls  of vit B6   Immunodiagnostik, Germany. 
 
-1,4-Dithiothreitol (C4H10O2S2)   Merck, Germany. 
 
- DL- (2-Amino-2-Carboxyethyl)-   CDN isotopes, Canada. 
   homocysteine 3,3,4,4-d4 (cystathionine-d4) 
 
 - DL-Homocysteine-3,3,3’, 4,4,4’, 4, -d8  CDN isotopes, Canada. 
    (homocysteine-d8).  
 
- DNA isolation kit     Qiagen, Germany. 
 
- DNA-Standard 1 KB    Gibco BRL, Germany.  
   
- d NTP- mix      Promega, Germany. 
 
- Ethidium bromide     Karlsruhe, Germany. 
 
- EDTA (triplex®-Π)     Merck, Germany. 
 
- Ethanol absolute     Merck, Germany.  
 
- Folate reagent and calibrators   Bayer diagnostics, Germany. 
 
- Methanol for chromatography   Merck, Gerrmany. 
 
- Methyl-d3-Malonic Acid    CDN isotopes, Canada. 
 
- Mobile phase of vitamin B6   immunodiagnosik, Germany.  
      
- MTBDSFA       Machery and Nagel, Germany. 
 
- Potassium bicarbonato    Merck, Germany. 
 
- Protenase K      Merck, Germany. 
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- PCR buffer      Roche, Germany. 
 
- PCR- water      Eppendorf, Germany. 
 
- Primers      Gibco BRL, Germany. 
  
- Reagent of ALT (GPT)    Roche, Germany 
 
- Reagent of AST (GOT)    Roche, Germany  
 
- Reagent of Bilirubin    Roche, Germany. 
 
- Reagent of cholesterol    Roche, Germany. 
 
- Reagent of creatinine    Roche, Germany. 
 
- Reagent of folic acid    Bayer, Germany. 
 
- Reagent of HoloTc-П    Axis-Shield, Norway. 
 
- Reagent of HDL-C plus    Roche, Germany. 
 
- Reagent of triglycerides    Roche, Germany. 
 
- Reagent of vitamin B12    Roche, Germany. 
 
- Reagent of urea     Roche, Germany. 
 
- Reagent of uric acid     Roche, Germany. 
 
- Restriction enzyme Hinf Ι    MBI, Germany. 
 
- Sodium Dodecyl Sulphate    Merck, Germany. 
 
- Sodium chlorid     Merck, Germany. 
 
- Ammonium chloride    Merck, Germany. 
 
- Tag polymerase     Roche, Germany. 
 
- TBE-buffer      GibcoBRL, Germany. 
 
- Tris (hydroxymethyle)-    Merck, Germany.  
   Aminomethan. 
 
- Vit B6 HPLC-kit     immunodiagnosik, Germany. 
 
- Vit B12 reagentss and calibrators   Bayer diagnostics, Germany. 
   
- Water for chromatography    Merck, Germany. 
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Instruments 
- ADVIA Centaur     Bayer diagnostics, Germany. 
 
- Balance ME215P     Sartorius, Göttingen. 
 
- Centrifugator EBA 12    Hettich, Tuttlingen. 
 
- Electrophoresis tank    Biotec Fisher, Reiskirchen. 
 
- Florescence detector G1321A   Agilent, Böblingen. 
 
- Gas chromatography HP 6890   Hewlett Packard, USA 
 
- Hitachi 911      Roche, Mannheim. 
 
- HPLC Agilent 1100     Agilent, Böblingen. 
 
- Mass-spectrometer HP 5973   Hewlett Packard, USA. 
 
- Mixer      Scientific Industry, USA. 
 
- Piptten      Eppendorf, Hamburg. 
 
- Robocycler® Gradient 96    Stratagene, USA. 
 
3. 8. Statistics 
SPSS 11.0 for Windows 98 was used for all statistical analyses. Kolmogorov-Smirnov 
criterion was used to asses the normal distribution of the continuous variables. All variables 
were not normally distributed and, thus, data were log-transformed to normalize distribution 
due to their skewed distribution. Data are presented as medians (10th-90th percentile), or 
number of subjects and percentage. Medians in tow independent groups or several 
independent groups were compared using nonparametric Mann-Whitney test and Kruskal-
Wallis test, respectively. The chi-square test was applied to assess differences in frequencies 
of measured variables. Spearmans’s rank correlation was determined to identify significant 
correlations between continuous variables. Further data analysis was performed in a subgroup 
that consisted of 63 pairs of age and gestation-age-matched patients and controls. Differences 
in biochemical markers between the matched pairs were assessed using a paired t-test. All 
tests were two-sided, and probability values < 0.05 were considered significant. The risk of 
HHcy (Hcy > 8.2 µmol/L) and preeclampsia disorder were computed by a logistic regression 
analysis. 
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4. RESULTS 
 
4. 1. Anthropometric and anamnestic data   
The study samples consisted of 275 pregnant Syrian women. Ninety-eight subjects (35.6 %) 
were normotensive throughout their pregnancy and served as control group (Con), 177 (64.4 
%) developed preeclampsia (PE). Of them 24 women developed eclampsia, the severe form of 
preeclampsia. Anthropometric and reproductive data are shown in table 4.1. Briefly, median 
maternal age did not differ between patient and control subjects. preeclampsia was found to 
be more prevalent in women at both extremes of reproductive age, ≤ 19 years and ≥ 35 years. 
Preeclamptic women delivered significantly earlier than normotensive women. Pre-term 
deliveries (gestational age < 37 weeks) were found in 45.2 % of preeclamptic women. Of 
them 22.5 % were affected by eclampsia. Low (< 2500 gram, g) and very low birth-weight (< 
1500 g) were found in 34 % and 17 %, respectively, of newborns of the preeclamptic women. 
Fetal death occurred in 18 % of cases delivered between 24 and 40 weeks. Women with 
preeclampsia had a higher median body mass index (kg/m2) than controls (29.3 vs. 27.1 
kg/m², P = 0.006). Cesarean section was done in 35 % of cases and vaginal delivery was done 
in 47 % of cases. In preeclampsia, cesarean sections were significantly more frequent in 
subjects with a BMI ≥ 25 compared to those with a BMI < 25 (34.3 % vs. 13.3 %). The 
prevalence of hypertension was more in primigravida (55.2 %) than in multigravida (44.2 %). 
Smoking status in study groups did not differ. However, only a very low percent of women 
were considered smokers (2 % controls and 5 % patients). 
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Table 4. 1. Characterization of subjects 
Data are presented as medians (10th-90th percentile), unless otherwise mentioned. * significant 
difference vs. controls.  ‡ Chi-square test. 
 
 
 
 
 
                                                 
1 PTD: preterm delivery 
2 VLBW: Very low birth weight  
3 LBW: Low birth weight 
4 BMI: Body mass index (kg/m2) 
Characteristic 
    
Controls (n = 98) 
 
Preeclampsia (n = 177) 
  
- Age, years 
       ≤ 19 years, n (%) 
       ≥ 35 years, n (%) 
25 (19-36) 
14 (14.4 %) 
12 (12.4 %) 
26 (18-38) 
33 (18.8 %) 
46 (26.1 %)‡ 
 
- Gestational age at recruitment, wk. 
- PTD1<37  wk. 
 
35 (29-40) 
NA 
37 (30-40)* 
80 (45.2 %) 
- Birth weight, (g) 
    VLBW2 <1500 g,  (%) 
        LBW3 <2500 g,  (%) 
       Still birth, (%) 
 
NA 
NA 
NA 
NA 
2400 (1100-3420) 
17 % 
34 % 
18 % 
- Maternal weight, kg 
- Maternal height, cm 
- BMI4, Kg/m² 
      BMI < 25, (%) 
      Overweight, (%) 
      Obsesity, (%) 
71 (59-86) 
160 (153-166) 
27.1 (24.4-33.5) 
21 % 
51 % 
28 % 
 
75 (60-95)* 
160 (152-167) 
29.3 (24.6-37.0)* 
11 % 
48 % 
42 % 
- Delivery 
     Normal, (%) 
     Cesearian, (%) 
     
 
NA 
NA 
 
 
47 % 
35 % 
- Parity 
      Nulliparity, n (%) 
      1 child, n (%) 
      > one child, n (%) 
 
39 (39.8 %) 
25 (25.5 %) 
34 (34.7 %) 
 
 
97 (54.8 %) 
16 (9.0 %) 
64 (36.2 %) 
 
- Smoking 
     No, (%) 
     Yes, (%) 
 
98 % 
2 % 
 
 
95 % 
5 % 
 
- Vitamin use, n (%) 
     beginning of supplementation 
     Duration of supplementation, wk 
 
88 (91 %)‡ 
9 
19 
103 (63 %) 
9 
8* 
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4. 2. General medical examination 
Serum concentrations of creatinine, urea, uric acid, liver enzymes, cholesterol (Chol), 
triglycerides (TG), and HDL-cholesterol (HDL-Chol) are summarized in table 4. 2. Median 
serum levels of creatinine, urea, and GOT were significantly higher in patients compared to 
controls. Similar result was observed for uric acid (6.6 vs. 4.0 mg/dl, P < 0.001). Of note, 
serum uric acid concentrations were significantly higher in women who developed eclampsia 
as compared to those who developed preeclampsia (7.3 vs. 6.5 mg/dl, p = 0.008). Serum Chol 
and TG levels were elevated in all groups, and were significantly higher in preeclampsia than 
in controls. No differences were seen in HDL-Chol between study groups. The same results 
were obtained after adjusting for the gestation age at inclusion.  
 
 
Table 4. 2. The parameters of medical characteristic of the study groups 
Data are presented as medians (10th-90th percentile). * significant difference vs. controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Controls, (n = 98) Preeclampsia, (n = 177)   Reference interval 
Creatinine, mg/dl 0.57 (0.45-0.69) 0.71* (0.53-0.95) ≤ 0.9  
Uric acid, mg/dl 4.0 (3.1-5.7) 6.6* (4.7-9.1) 2.4-5.7 
Urea, mg/dl 14 (9-21) 24* (15-38) 10-50 
GPT, U/L 12 (8-20) 12 (7-62) < 34 
GOT, U/L 19 (14-26) 25* (16-92) < 37 
Chol, mg/dl 246 (194-330) 279* (192-409) ≤ 200 
TG, mg/dl 252 (174-400) 335* (186-592) ≤ 200 
LDL-Chol, mg/dl 133 (83-212) 142 (78-236) 60-140 
HDL-Chol, mg/dl 58 (42-79) 61 (43-82) 33-55 
RR sys ___________ 160 (140-180)  
RR diast ___________ 100 (90-120)  
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4. 3. Hcy and B-vitamin status 
Median tHcy level was significantly higher in preeclamptic women compared to controls 
(table 4. 3). Since there is no established reference range for tHcy level during pregnancy, 
elevated tHcy was defined as a serum tHcy level > 8.2 µmol/L. This value represents the 95th 
percentile of Hcy concentration among normotensive women who had adequate status of vit 
B12 and folate. Accordingly, elevated tHcy levels (tHcy > 8.2 µmol/L) were more prevalent 
in preeclamptic women (65.2 %) than in controls (22 %) (figure 4. 1). Preeclamptic women 
had significantly higher Cys levels than controls. Fifty-eight percent of patients but only 23 % 
of controls had Cys levels above the upper reference limited (URL) (URL: Cys > 301 
nmol/L). Impaired cobalamin status was seen in a high frequency in patients and controls. 
Nearly 60 % of all subjects had vit B12 deficiency (serum vit B12 < 211 pg/ml), and an even 
higher proportion (77.7 %) and (64.6 %) exhibited low holoTC and elevated MMA, 
respectively. Vit B6 deficiency (vit B6 < 4.3 ng/ml) was very frequent in both groups (82 % 
of contros and 88.3 % of patients). Figure 4. 1 illustrates the prevalence of abnormal Hcy, 
Cys, MMA, and B-vitamins in all groups.   
 
 
 
    tHcy               Vit B12 MMA               HoloTc      Cys              Vit B6             Folate      
         > 8.20 µmol/L    < 211 pg/ml    > 271 nmol/L    < 35 pmol/L    > 301 nmol/L     <4.3 ng/ml       < 5 ng/ml   
Figure 4. 1. The prevalence of abnormal metabolites and B-vitamins levels in controls and 
patients 
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Median folate concentrations was significantly lower in preeclamptic women (7.3 ng/ml) 
compared to controls (15.9 ng/ml). Folate deficiency (folic acid < 5 ng/ml) was observed in 5 
% of controls versus in 19 % of preeclampsia (figure 4. 1). Furthermore, normotensive 
pregnant women used more frequently vitamin supplementation than patient women (91 % vs. 
63 %, P < 0.001) (figure 4. 2). Vitamin supplementation mainly included folic acid at a daily 
dose of 0.5-5 mg. In folic acid-supplemented women, supplementation was initiated on 
average at 9 weeks of gestation in both groups, and continued for an average duration of 19 
weeks in controls and 8 weeks in preeclamptic women (p < 0.001). As expected, folic acid 
supplementation during pregnancy improved the folate status. Supplemented women had 
significantly higher folate levels in both patients (8.5 vs. 5.7 ng/ml, P < 0.001) and controls 
(15.8 vs 8.8 ng/ml, P= 0.048). Additionally, supplemented patient women had significantly 
lower folate levels compared to supplemented normotensive women (8.5 and 15.8 ng/ml, 
respectively, P < 0.001) (figure 4. 3). Furthermore, supplementation associated with relatively 
lower levels of tHcy in both group (figure 4. 3). These differences remained significant after 
adjusting for the gestation age at inclusion.  
 
 
 
Figure 4. 2. Scatter plots of folic acid concentrations in supplemented and un-supplemented 
women. □ supplemented women, + un-supplemented women. 
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Figure 4. 3. serum tHcy and folate in supplemented and unsuplemented pregnant women 
 
 
We conducted data analysis of 63 pairs of controls and patients who were matched for 
maternal age and gestational age (table 4. 3). Serum concentration of Hcy and Cys were 
significantly higher, and serum concentrations of folate and PLP were significantly lower in 
patients compared to healthy women. Vit B12 status, indicated either by measurement of 
serum vit B12 or by MMA and holoTC did not differ significantly between patients and 
controls. In patients group, holoTC correlated significantly to creatinine (r = + 0.28, p < 
0.001).  
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Table 4. 3. Concentrations of metabolites and vitamins in 63 age-and gestational-age-matched 
pairs of pregnant women 
Data are presented as medians (10th-90th percentiles). Subject age, 25 (19-36) years and 
gestational age , 36 (30-40). * significant difference vs. controls  
 
 
 
Levels of Hcy and Cys were found to be elevated in the serum of individuals with subnormal 
vit B12 status (Stabler et al., 1993). Additionally, normal- to high-normal levels of folate are 
common in vit B12-deficient subjects. Recently, a high incidence of vit B12 deficiency was 
reported in Syria (Herrmann et al., 2003; Obeid et al., 2002). Therefore, aiming to eliminate 
the influence of vit B12 deficiency, we compared B-vitamins levels and the metabolites only 
in individuals with normal cobalamin status (MMA ≤ 271 nmol/L ) and renal function 
(creatinine ≤ 0.9 mg/dl). Significantly higher levels of tHcy, Cys and lower levels of folate, 
vit B6, and vit B12 were found in preeclamptic women as compared to controls (table 4. 4). 
These differences remained significant after adjusting for the gestation age at inclusion. 
 
 
 
 
 
 
 
 
 
 Controls (n = 63) 
 
Preeclampsia (n = 63) 
 
tHcy, µmol/l 
 
6.0 (4.5-9.7) 
 
9.3 (6.8-14.6)* 
 
Folate, ng/ml 15.9 (5.9-26.6) 
 
7.3 (4.2-12.3)* 
 
Vit B12 status 
        Vit B12, pg/ml 
        MMA, nmol/L 
        HoloTC, pmol/L 
 
218 (144-294) 
296 (143-660) 
23 (9-64) 
 
 
182 (114-294) 
323 (134-618) 
25 (14-79) 
 
Vit B6 status 
        PLP, ng/ml 
        Cys, nmol/L 
 
 
 
2.4 (1.2-7.6) 
232 (170-392) 
 
 
2.0 (0.9-4.2)* 
284 (177-556)* 
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Table 4. 4. Meth metabolites and B-vitamins of the study groups with MMA < 271 nmol/L 
Data are presented as medians (10th-90th percentile). * significant difference vs. controls. Only 
subjects with normal renal function were included. 
 
 
4. 4. Correlation analyses 
As expected, birth weight correlated strongly with the gestation age in preeclamptic women (r 
= + 0.73, P < 0.001). Overall, neither the metabolites (Hcy, Cys, MMA) nor B-vitamins 
(folate, vit B12, vit B6) showed significant association with maternal age. In normotensive 
women, gestation age was positively correlated to Hcy, Cys, and MMA, and negatively to 
serum B-vitamins (figure 4. 4), which may partly explain elevated the metabolites and 
decreased B-vitamins seen in controls when the pregnancy progresses (table 4. 10). On the 
contrary, no such correlations were found in preeclamptic women with exception of vit B6 
(figure 4. 4). 
 
 
 
 
 
 
 
 
 
 
 
 Normotensive (normal MMA) 
 N = 41 
Hypertensive (normal MMA) 
N = 48 
Hcy, µmol/l 
 
5.3 (3.8-6.8) 
 
8.2 (6.6-14.9)* 
Folate, ng/ml 
 
17.2 (8.5-27.5)  8.2 (3.5-18.1)* 
 
Vit B12 status 
       Vit B12, pg/ml 
       MMA, nmol/L 
       HoloTC, pmol/L 
 
 
232 (168-348) 
188 (118-255) 
30 (19-70) 
 
197 (94-406)* 
193 (124-261) 
  25 (10-86) 
Vit B6 status 
       PLP, ng/ml 
       Cys, nmol/L 
 
 
2.5 (1.6-9.3) 
229 (139-393) 
 
2.0 (0.9-6.7)* 
293 (194-524)* 
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Figure 4. 4. The association between gestation age and the metabolites (left panels) and B-
vitamins (right panels) in control and patients groups.  o  patients, o  controls 
 
 
 
In all women who ever used supplements during pregnancy, longer duration of vitamin 
supplementation was associated with lower tHcy levels and higher serum folate (figure 4. 5). 
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Figure 4. 5. Overall analysis of correlation between duration of vitamin supplementation, 
tHcy and folate 
 
 
4. 4. 1. Correlations between Hcy, MMA, vit B12, holoTC, and folate 
Serum tHcy concentrations correlated positively with serum folate in healthy and 
preeclamptic women. The correlation between Hcy and folate was stronger in controls 
compared to preeclamptic women (r = - 0.49 vs. – 0.29). A significant negative correlation 
between serum tHcy and holoTC (r = - 0.47, p < 0.001) was found among healthy pregnant 
women, and a marginal negative correlation (r = - 0.27, p = 0.062) was found in preeclamptic 
women. Likewise, the correlation between serum tHcy and vit B12 was significant only in 
normotensive women (r = - 0.27, p = 0.033). Nevertheless, Hcy correlated significantly to 
MMA in both groups. However, the correlation between concentrations of Hcy and MMA 
was much stronger in controls compared to preeclamptic women (figure 4. 6). 
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Figure 4. 6. The correlation between serum tHcy and that of holoTC, MMA, and folate in age-
and gestation age-matched controls and patients (n = 63 pairs). O               controls,  ∆  
patients   
 
 
 
As expected, there were positive correlation between vit B12 and holoTC (controls: r = 0.53, 
p < 0.001; patients: r = 0.59, p < 0.001), and negative correlation between vit B12 and MMA 
(controls: r = - 0.33, p = 0.007; patients: r = - 0.34, p = 0.001). Additionally, serum MMA 
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correlated negatively and significantly to holoTC (figure 4. 7) (controls: r = - 0.40, p = 0.002; 
preeclampsia: r = - 0.30, p = 0.038).  
 
 
Figure 4. 7. The correlation between serum MMA and that of holoTC, and vit B12 in age-and 
gestation age-matched controls and patients (n = 63 pairs). O          controls,  ∆  patients   
 
 
 
The correlation between the metabolites and other vitamins are shown in table 4. 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
Table 4. 5. Spearman rank-rho correlation coefficient of the metabolites and B-vitamins in the 
whole study groups (A: total population; B: control group; C: preeclamptic group). All 
correlations were adjusted for maternal and gestational age 
A 
          
Overall 
(n = 275)          
   Hcy Cys MMA vit B12 folate holo TC vit B6 M.A. G.A. BMI 
Hcy  r   0,54 0,38 -0,22 -0,52 -0,3 -0,23 0,03 0,17 0,14 
  P   <0,001 <0,001 <0,001 <0,001 <0,001 <0,001 0,65 0,005 0,032 
Cys r     0,21 -0,12 -0,21 -0,11 -0,28 0,08 0,22 0,07 
  P     <0,001 0,048 0,001 0,12 <0,001 0,17 <0,001 0,26 
MMA r       -0,31 -0,18 -0,38 -0,12 0,01 0,13 0,03 
  P       <0,001 0,003 <0,001 0,053 0,94 0,032 0,61 
vit B12 r         0,23 0,48 0,27 0,03 -0,16 -0,12 
  P         <0,001 <0,001 <0,001 0,59 0,011 0,062 
folate r           0,31 0,15 0,09 -0,18 -0,07 
  P           <0,001 0,012 0,16 0,004 0,31 
holoTC r             0,26 0,06 -0,1 -0,04 
  P             <0,001 0,35 0,16 0,57 
vit B6 r               -0,02 -0,3 -0,14 
  P               0,71 <0,001 0,027 
M.A. r                 0,03 0,39 
  P                 0,58 <0,001
G.A. r                   0,2 
  P                   0,002 
 
B 
          
Controls 
(n = 98)          
   Hcy Cys MMA vit B12 folate holo TC vit B6 M.A. G.A. BMI 
Hcy  r   0.38 0,65 -0,28 -0,41 -0,50 -0,14 0.10 0,46 -0,01 
  P   <0,001 <0.001 0,005 <0,001 <0,001 0,16 0,34 <0,001 0,93 
Cys r     0,18 -0,11 -0,12 -0,05 -0,31 0,22 0,29 0,19 
  P     0,068 0,27 0,24 0,69 0,002 0,028 0,003 0,061 
MMA r       -0,38 -0,22 -0,45 -0,12 -0,07 0,26 -0,13 
  P       <0,001 0,029 <0,001 0,25 0,48 0,012 0,2 
vit B12 r         0,06 0,44 0,2 -0,04 -0,22 -0,07 
  P         0,56 <0,001 0,047 0,69 0,029 0,52 
folate r           0,32 0,08 0,12 -0,32 -0,03 
  P           0,003 0,41 0,26 0,002 0,76 
holoTC r             0,19 0,17 -0,14 0,03 
  P             0,086 0,12 0,2 0,77 
vit B6 r               -0,17 -0,26 -0,11 
  P               0,087 0,011 0,3 
M.A. r                 0,08 0,33 
  P                 0,45 0,001 
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G.A. r                   0,2 
  P                   0,058 
 
C 
          
Patients 
(n = 177)          
   Hcy Cys MMA vit B12 folate holo TC vit B6 M.A. G.A. BMI 
Hcy  r   0,44 0,31 -0,05 0,32 -0,24 -0,16 0,02 -0,06 0,07 
  P   <0,001 <0,001 0,5 <0,001 0,006 0,032 0,78 0,41 0,4 
Cys r     0,18 0,02 -0,01 -0,08 -0,19 0,03 0,12 -0,07 
  P     0,015 0,81 0,96 0,37 0,011 0,69 0,11 0,39 
MMA r       -0,26 -0,12 -0,33 -0,11 0,06 0,05 0,12 
  P       <0,001 0,12 <0,001 0,16 0,47 0,55 0,16 
vit B12 r         0,16 0,5 0,23 0,05 -0,08 -0,08 
  P         0,032 <0,001 0,002 0,55 0,27 0,32 
folate r           0,29 0,05 0,06 -0,04 0,05 
  P           0,001 0,53 0,46 0,62 0,55 
holoTC r             0,3 -0,01 -0,05 -0,06 
  P             <0,001 0,92 0,57 0,54 
Vit B6 r               0,04 -0,28 -0,14 
  P               0,59 <0,001 0,11 
M.A. r                 0,01 0,44 
  P                 0,95 <0,001
G.A. r                   0,16 
  P                   0,054 
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Interaction between folate and vit B12 as determinants of tHcy levels 
The influence of folate status on tHcy levels depends on functional vit B12 status. Medians 
tHcy levels were presented in two subgroups within three folate tertiles. Both subgroups of 
controls had no significant differences in folate concentration in each tertile of folate. 
Normotensive pregnant women with normal levels of MMA (MMA ≤ 271 nmol/L) achieved 
lower tHcy levels at already lower levels of folate compared with normotensive pregnant 
women with elevated MMA (MMA > 271 nmol/L). Additionally, at the same level of folate 
pregnant women with abnormal level of MMA showed significantly higher tHcy levels 
compared to their counterparts with normal MMA levels. Serum vit B6 did not differ between 
these two subgroups of MMA within each tertile of folate. Of note, serum tHcy correlated 
significantly to MMA levels (r = 0.46, p = 0.002) in individuals with normal MMA levels, 
and to folate (r = - 0.56, r < 0.001) and MMA (r = 0.39, p = 0.003) in individuals with 
abnormal MMA levels (data not shown). These observations may indicate the increased 
requirement for folate in individuals with subnormal vit B12 status (figure 4. 8). 
 
  
  
 
Figure 4. 8. Medians tHcy levels in different tertiles of folate. Lines represent healthy 
pregnant women; with MMA ≤ 271nmol/L or with MMA > 271nmol/L. Only subjects with 
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normal renal function (creatinine ≤ 0.9 mg/dl) and folate > 5 mg/ml were included. * 
significant difference vs. controls within each tertile of folate 
 
Compared with normotensive women, preeclamptic women required higher folate levels to 
achieve the same levels of Hcy seen in controls (figure 4. 9). 
 
 
 
Figure 4. 9. The correlation between tHcy and folate in controls and preeclamptic women. 
Preeclamptic women had higher folate requirement to maintain similar tHcy levels as that in 
normotensive women    
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4. 4. 2. Correlations between creatinine, uric acid, the metabolites and B-vitamins  
As expected, creatinine, uric acid, and urea correlated to each other in both groups. Serum 
creatinine was positively correlated to tHcy, Cys, and MMA in both groups. The correlation 
between creatinine and holoTC was significant only in preeclamptic women (table 4. 6).  
 
 
 
Table 4. 6. Spearman rank-rho correlation coefficient of renal function, the metabolites, 
 and B-vitamins 
  Overall (n = 275)   Controls (n = 98)   Patients (n = 177)  
   Crea Uric A. Urea Crea Uric A. Urea Crea Uric A. Urea 
Hcy r 0,51 0,57 0,44 0,42 0,29 0,042 0.33 0,31 0,21 
  P <0,001 <0,001 <0,001 <0,001 0,003 0,68 <0,001 <0,001 0,006 
Cys r 0,42 0,41 0,39 0,23 0,27 0,09 0,36 0,25 0,28 
  P <0,001 <0,001 <0,001 0,021 0,006 0,37 <0,001 0,001 <0,001
MMA r 0,19 0,13 0,1 0,28 0,054 0,041 0,16 0,12 0,069 
  P <0,001 0,035 0,08 0,004 0,59 0,69 0,034 0,1 0,36 
vit B12 r 0,037 -0,07 0,005 0,099 0,04 0,27 0,21 0,18 0,21 
  P 0,54 0,27 0,93 0,33 0,69 0,008 0,005 0,016 0,005 
folate r -0,21 -0,26 -0,19 -0,21 -0,09 -0,058 0,072 0,11 0,13 
  P <0,001 <0,001 0,002 0,037 0,36 0,57 0,34 0,16 0,087 
Holo TC r 0,17 0,09 0,19 0,066 0,05 0,27 0,28 0,23 0,28 
  P 0,014 0,21 0,006 0,55 0,65 0,012 0,001 0,01 0,001 
vit B6 r -0,07 -0,07 0,02 -0,034 0,007 -0,018 0,076 0,13 0,32 
  P 0,25 0,29 0,69 0,74 0,94 0,86 0,31 0,088 <0,001
M.A. r -0,03 0,04 0,002 0,14 0,23 0,11 -0,08 -0,023 -0,054 
  P 0,68 0,53 0,97 0,17 0,001 0,27 0,28 0,77 0,48 
G.A. r 0,06 0,09 -0,03 0,46 0,42 0,078 -0,2 -0,19 -0,29 
  P 0,36 0,13 0,65 <0,001 <0,001 0,44 0,07 0,013 <0,001
BMI r 0,06 0,17 0,06 0,19 0,27 0,032 -0,16 -0,023 -0,14 
  P 0,39 0,01 0,34 0,066 0,009 0,76 0,065 0,79 0,11 
Crea r   0,71 0,63   0,52 0.33   0,6 0,54 
  P   <0,001 <0,001   <0,001 0,001   <0,001 <0,001
Uric A. r     0,67     0,23     0,51 
  P     <0,001     0,02     <0,001
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4. 5. MTHFR genotypes 
The prevalence of MTHFR C677T 
The frequency of the homozygous 677C→T (T/T) genotype was 8.8 % in all subjects with a 
mutant allele frequency of 31.1 %. Distribution of the three genotypes did not differ between 
the groups (p = 0.224, χ²- test). Table 4. 7 summarizes the distribution of the MTHFR in the 
three groups.  
 
 
Table 4. 7. Frequency of MTHFR 677 C→T genotypes in healthy and preeclamptic women 
Genotype All subjects (n = 272) Controls (n = 97) Patients (n = 175) 
CC 127 (46.7 %) 38 (39.2 %) 89 (50.8 %) 
CT 121 (44.5 %) 47 (48.4 %) 74 (42.3 %) 
TT 24 (8.8 %) 12 (12.4 %) 12 (6.9 %) 
CC: wildtype, CT: heterozygotes, TT:homozygotes 
Note. DNA not available for 1 control and 2 preeclamptic women  
 
 
 
Folate, vit B12, and tHcy concentrations were studied in relation to the MTHFR genotypes 
(table 4. 8). The presence of T-allele did not have influence on these variables. In both groups, 
subjects who were homozygous or heterozygous for the mutant allele did not exhibit 
significant differences in tHcy, folate, and vit B12 as compared to subjects with CC genotype. 
Compared to controls, serum tHcy level was significantly higher and folate and vit B12 were 
significantly lower in preeclamptic women among subjects with CC and CT genotypes, 
whereas similar concentrations among subjects with TT genotype were seen (table 4. 8). 
Maternal age and gestational age which are potential confounders of tHcy levels, did not 
differ between subjects with CC and those with CT or TT genotypes in controls and patients 
groups 
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Table 4. 8. Maternal tHcy, folate, and vit B12 concentrations according to the MTHFR 
genotypes 
Data are presented as medians. CC: wildtype, CT: heterozygotes, TT:homozygotes. P1: 
Kruskal Wallis test by genotype, P: Mann-Whitney test by study groups.  
 
 
Even that the medians of tHcy did not differ among the three genotypes (CC, CT, TT), the 
incidence of HHcy (Hcy > 8.2 µmol/L) was highest in subjects with the TT genotype 
compared to the other two genotypes in each study group (figure 4. 10). Morethat, HHcy was 
more frequent in preeclamptic women compared to the controls within each MTHFR 
genotype. 
 
 
 Con/PE, n CC (38/89) CT (47/74) TT (12/12) P1- value 
Hcy, µmol/L Controls 
Patients 
6.2 
9.7 
6.1 
9.6 
8.2 
10.6 
0.234 
0.307 
P-value  <0.001 <0.001 0.178  
Folate, ng/ml Controls 
Patients 
15.6 
8..1 
15.6 
8.2 
7.3 
6.3 
0.068 
0.463 
P-value  <0.001 <0.001 0.410  
Vit B12, pg/ml Controls 
Patients 
216 
182 
217 
161 
187 
217 
0.312. 
0.129 
P-value  0.023 <0.001 0.843  
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Figure 4. 10. The prevalence of HHcy (Hcy > 8.2 µmol/L) according to the MTHFR 
genotypes 
The interaction between  folate status and MTHFR genotypes as determinants of Hcy 
Table 4. 9 shows tHcy and folate concentration among MTHFR genotypes in two ranges of 
folate status. Maternal and gestation age did not differ significantly within MTHFR genotypes 
(CC, CT, TT) in both folate levels (folate ≤ 8.9 ng/ml, folate > 8.9 ng/ml). The influence of 
MTHFR TT genotype on tHcy level was seen only when folate was ≤ 8.9 ng/ml. As shown, 
the TT group had significantly higher tHcy levels than CC (median tHcy:11.3 vs. 9.6 µmol/L, 
p = 0.027) when folate was ≤ 8.9 ng/ml, whereas this difference disappeared when folate was 
above 8.9 ng/ml (figure 4. 11). Increased tHcy levels seen in the TT group with folate ≤ 8.9 
ng/ml accompanied with significant lower levels of folate (4.5 ng/ml) as compared with either 
CC (6.5 ng/ml) or CT (6.3 ng/ml) groups (p = 0.004 and 0.006, respectively) (table 4. 9).  
 
 
Table 4. 9.  Serum tHcy and folate concentrations of women according to MTHFR genotypes 
within two folate range  
 Genotypes Total population 
( folate ≤ 8.9 ng/ml) 
N = 136 
Total population 
( folate > 8.9 ng/ml) 
N = 136 
Hcy, µmol/L CC 
CT 
TT 
9.6a 
9.6a 
11.3* 
 
7.4a 
7.0a 
6.8a 
P1- value  0.083 0.720 
Folate, ng/ml CC 
CT 
TT 
6.5 
6.3 
4.5*† 
14.0 
15.4 
13.4 
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P1- value  0.012 0.838 
Maternal age, years CC 
CT 
TT 
25 
25 
23 
26 
27 
32 
P1- value  0.228 0.731 
Gestational age, weeks CC 
CT 
TT 
37 
37 
38 
37 
35 
36 
P1- value  0.869 0.055 
Data are presented as medians. P1: Kruskal Wallis test by genotype. Values with identical 
superscript letters are not significantly different. * significant as compared with CC, † 
significant as compared with CT. The cutt-off value of folate represents the median of folate 
in the total population 
 
 
 
  
Figure 4. 11. Median of tHcy and folic acid among MTHFR genotypes in two ranges of folate  
status (folate ≤ 8.9 ng/ml and > 8.9 ng/ml). P represents the significance of difference 
between CC and TT genotypes 
 
 
 
4. 6. Determinants of Hcy, Cys, and MMA levels 
Logistic regression analysis with backward elimination was used to determine the factors that 
independently influenced Hcy, Cys, and MMA levels in healthy and preeclamptic women 
(table 4. 10). In both groups, Hcy was inversely and independently influenced by cobalamin 
and folate status, and positively by Cys. In healthy pregnant women, tHcy level was more 
influenced by cobalamin status  than by folate status. Renal function indicated by creatinine 
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had an independent influence on the Hcy, Cys, and MMA levels only in preeclamptic women, 
suggesting that preeclampsia related renal dysfunction accounts for some of these metabolites 
elevations.  
 
 
 
 
 
 
 
 
 
Table 4. 10. The final model of the backward regression analysis with Hcy, Cys and MMA as 
dependent variables  
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 Beta: is the regression coefficient and interpreted as the amount of change in the dependent 
variable with one unite of change in the independent variable. R-square: the coefficient of 
determination and shows the strength of the relationship between the model and the dependent 
variables. Variables with skewed distribution were logarithmic transformed for normality. In 
addition to the variables that appeared in the final model, other variables were entered in the 
test  (duration of vitamin supplementation, maternal age, gestational age, Urea, holoTC, BMI, 
and MTHFR C→T genotypes).   
 
 
 
 
 
 
Dependent variables Independent variables in the final 
model 
Beta P-value. R-square 
Healthy women      
Hcy 
 
 
 
MMA 
 
 
Cys 
 
 
 
 
Cys  
MMA 
Folate 
 
Hcy 
Vit B12 
 
Hcy  
Vit B12 
Vit B6 
 
 
+ 0.26 
+ 0.23 
-  0.14 
 
+ 0.94 
-  0.54 
 
+ 0.41 
+ 0.27 
- 0.23 
 
 
 
  0.001 
<0.001 
  0.008 
   
<0.001 
  0.002 
   
<0.001 
  0.006 
  0.016 
 
 
 
 
R² = 0.48 
 
 
R² = 0.37 
 
 
 
R² = 0.25 
Preeclamptic women       
Hcy 
 
 
 
 
MMA 
 
 
 
 
 
Cys 
Creatinine 
Cys 
Folate 
MMA 
 
Creatinine 
Vit B12 
Hcy 
MTHFR TT 
Vitamin use 
 
Hcy  
Creatinine 
Vit B6 
BMI 
 
 
+ 0.33 
+ 0.29 
- 0.26 
+ 0.13 
 
+ 0.49 
-  0.40 
+ 0.39 
-  0.17 
-  0.14 
 
+ 0.34 
+ 0.26 
- 0.21 
- 0.20 
  0.005 
<0.001 
<0.001 
  0.004 
 
  0.023 
<0.001  
  0.003 
  0.039 
  0.002 
 
<0.001 
  0.001 
  0.009 
  0.017 
 
R² = 0.40 
 
 
R² = 0.31 
 
 
 
 
 
R² = 0.33 
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4. 7. The metabolites and B-vitamins concentrations according to 
the gestational age 
 
Subjects were stratified according to their gestation age to investigate a possible association 
between the vitamins and the metabolites in patients and controls of comparable age of 
gestation (table 4. 11). Significant higher tHcy and Cys levels were seen in preeclamptic 
women as compared to controls in each category of the gestation age (table 4. 11). 
Additionally, differences in serum concentrations of folate, vit B12, and vit B6 were 
observed. Within each study group, pregnant women in the age ≤ 34 wk of gestation had 
relatively higher B-vitamins levels compared to those who were late in their pregnancy (i.e., 
those with gestational age > 38 wk). More that, in the control group a significant increase in 
tHcy, Cys, and MMA concentrations occurred with increasing gestation, whereas 
preeclamptic women had elevated levels from these metabolites earlier in their gestation. 
(figure 4. 13). The cut-off value for HHcy was identified in each tertile of gestation age as the 
95th percentile of Hcy concentration in normotensive pregnant women who had normal renal 
function. Accordingly, the cut-off values were 10.3, 11.0, and 15.7 µmol/L in the first, 
second, and the third tertile of gestation age, respectively. Using these values, HHcy was 
found in 41.8 %, 40.3 %, and in 8 % of preeclamptic women who were in the first, second, 
and the third tertile of gestation age, respectively. As shown in figure 4.12, the 95th percentile 
of Hcy concentrations was higher in preeclamptic women as compared to controls in each 
tertile of gestation age.         
 
 
Figure 4. 12. the 95Th percentile of Hcy concentrations in each tertile of gestation age 
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Table 4. 11. Serum concentration of the metabolites and vitamins according to the gestation 
P-value                                        0.228               0.037                 0.097 
Data are presented as medians. P1: significant by categories of gestational age, P: significant 
by study groups. % refers to the percent of prevalence of abnormal metabolites or vitamin 
deficiency 
 
 
 
 
 
 
Controls/patients, n 
 20-34 weeks 
46/55 
35-38 weeks 
30/72 
>38 weeks 
22/50 
P1- value 
Hcy (µmol/L) Controls 
Patients 
5.6 (10.9%) 
9.8 (6.7%) 
6.4 (16.7%) 
9.6 (62.5%) 
8.0 (50.0%) 
9.3 (66.0%) 
< 0.001 
0.890 
P-value  < 0.001 < 0.001 0.017  
Cys (nmol/L) Controls 
Patients 
226 (10.9%) 
315 (56.4%) 
241(23.3%) 
325 (56.9%) 
270 (40.9%) 
374 (62.0%) 
0.018 
0.367 
P-value  < 0.001 0.003 0.013  
MMA (nmol/L) Controls 
Patients 
263 (47.8%) 
320 (59.3%) 
337 (65.5%) 
346 (77.5%) 
469 (68.2%) 
339 (65.3%) 
0.031 
0.437 
P-value  0.141 0.690 0.654  
Vit B12 (pg/ml) Controls 
Patients 
226 (30.4%) 
186 (60.0%) 
208 (60.0%) 
169 (65.7%) 
187 (68.2%) 
164 (78.0%) 
0.042 
0.473 
P-value  0.003 0.018 0.092  
Folate (ng/ml) Controls 
Patients 
18.6 (4.3%) 
8.3 (18.2%) 
14.4 (3.3%) 
6.6 (22.9%) 
10.1 (9.1%) 
8.0 (16.0%) 
0.012 
0.241 
P-value  < 0.001 < 0.001 0.002  
HoloTC (pmol/L) Controls 
Patients 
20 (70.3%) 
21 (77.3%) 
22 (80.8%) 
22 (76.9%) 
24 (81.0%) 
21 (81.8%) 
0.480 
0.942 
P-value  0.301 0.774 0.993  
PLP (nmol/L) Controls 
Patients 
2.6 (80.4%) 
2.1 (75.9%) 
2.1 (86.7%) 
1.8 (95.7%) 
2.2 (90.9%) 
1.9 (98.0%) 
0.015 
< 0.001 
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Figure 4. 13.  Medians of Hcy, Cys, and MMA in relation to tertiles of gestation age. P*: in 
controls, p†: in preeclamptic women  
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4. 8. Odds ratio for HHcy  
Logistic regression analysis on the pooled data were applied to identify the effect of B-
vitamins and MTHFR genotypes on the risk of HHcy (Hcy > 8.2 µmol/L) in the pregnant 
women of the present study. For this purpose each subject classified once according to the 
quartiles of folate determined by the distribution of folate in the total population, and once 
according to the quartiles of MMA determined by the distribution of MMA in the total 
population. As shown in table 4. 12, the MTHFR genotypes and vit B6 had no significant 
influence on the risk of HHcy. In contrast, folate and vit B12 deficiency had significant 
influences, and the risk of HHcy associated with elevated MMA levels was higher than the 
risk associated with decreased folate levels. Pregnant women who were within the highest 
quartile of MMA had higher risk of HHcy than pregnant women who were within the lowest 
quartile of folate (9.78-fold and 7.03-fold increased risk of HHcy, respectively). This risk was 
higher when decreased folate levels was associated with elevated serum MMA levels or TT 
genotype (table 4. 12). 
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Table 4. 12. the odds ratio of HHcy risk (Hcy > 8.2 µmol/L) in pooled data 
 Adjusted OR (95 % CI)b P value 
MTHFR genotypes 
MTHFR CC  
MTHFR CT 
MTHFR TT 
 
Vit B6, ng/ml 
Q4 ≥ 3.0 
Q3 [2.2-2.9] 
Q2 [1.7-2.1] 
Q1 ≤ 1.6 
 
 
1.0 (referent) 
1.52 (0.69-3.34) 
2.28 (0.66-7.89) 
 
 
 
1.0 (referent) 
1.64 (0.50-5.32) 
2.05 (0.66-6.38) 
2.16 (0.71-6.51) 
 
 
0.29 
0.19 
 
 
 
 
0.41 
0.22 
0.17 
Folate, ng/ml 
Q4 ≥ 14.91 
Q3 [8.93-14.86] 
Q2 [6.20-8.90] 
Q1 ≤ 6.13 
 
1.0 (referent) 
2.81 (0.78-10.09) 
5.99 (1.68-21.36) 
7.03 (1.94-25.49) 
 
 
0.114 
0.006 
0.003 
 
MMA, nmol/L 
Q1 ≤ 217 
Q2 [218-337] 
Q3 [339-537] 
Q4 ≥ 540 
 
Combination (folate/MMA) 
Folate ≥ 14.91/MMA< 540 
Folate < 14.91/MMA ≥ 540 
 
MTHFR/folate 
MTHFR CC/folate ≥ 14.91 
MTHFR TT/folate < 14.91 
 
 
MTHFR/MMA 
MTHFR CC/MMA < 540 
MTHFR TT/MMA ≥ 540 
 
 
1.0 (referent) 
1.44 (0.50-4.09) 
4.55 (1.56-13.29) 
9.78 (3.10-30.86) 
 
 
1.0 (referent) 
39.40 (4.92-315.71) 
 
 
 
1.0 (referent) 
70.36 (3.54-1398.16) 
 
 
 
1.0 (referent) 
5.89 (0.58-59.42) 
 
 
 
 
0.50 
0.006 
< 0.001 
 
 
 
< 0.001 
 
 
 
 
0.005 
 
 
 
 
0.13 
The model was adjusted for potential confoundings: Maternal age, gestation age, study 
groups, creatinine, MMA, folate, vit B6, and MTHFR genotypes. 
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4. 9. Odds ratio for preeclampsia 
To estimate the odds ratio for PE according to the different variables of the current study 
(Hcy, folate, vit B12, and MTHFR genotypes), each subjects was classified once according to 
the quartiles of Hcy determined by the distribution of Hcy in controls, once according to the 
quartiles of folic acid determined by the distribution of folate in controls, and once according 
to the quartiles of MMA determined by the distribution of MMA in controls (table 4. 13).  
There was a significant association between maternal tHcy and folate status and the risk of 
preeclampsia. After adjustment for the potential confounding, women in the highest quartile 
of Hcy or in the lowest quartile of folate experienced increased risk of preeclampsia as 
compared with women in the lowest quartile of Hcy and in the highest quartile of folate, 
respectively (OR for Hcy = 21.6 (3.7-125.3); OR for folate = 9.9 (2.53-39.44)). After 
adjustment for the potential confounding, there was no clear association of preeclampsia risk 
and vit B12 status indicated by MMA. Logistic regression analysis was applied again to 
analyse the combined effect of folate status and MTHFR genotype on the occurrence of 
preeclampsia. As shown in table 4. 13, maternal folate concentration had a greater influence 
than MTHFR genotypes as a determinant of preeclampsia risk. Compared to women with 
folate ≥ 8.9 ng/ml and CC genotype (the referent group), women with low folate (folate < 8.9 
ng/ml) and CC genotype experienced 4.8-fold increased risk of preeclampsia. 
0 
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Table 4. 13. the odds ratio of preeclampsia risk  
 controls 
N = 97 
patients 
N = 175 
Adjusted OR (95 % CI)b P value 
HCY, µmol/L 
Q1 <5.2 
Q2 [5.2-6.1] 
Q3 [6.2-7.7] 
Q4 >7.8 
 
 
24 
24 
25 
24 
 
3 
8 
33 
128 
 
1.0 (referent) 
2.6 (0.39-16.5) 
7.3 (1.32-40.0) 
21.6 (3.7-125.3) 
 
 
0.321 
0.023 
0.001 
Folate, ng/ml  
Q4 >21.3  
Q3 [14.7-21.3]  
Q2 [8.7-14.6] 
Q1 <8.7 
 
 
25 
24 
24 
24 
 
8 
13 
49 
102 
 
1.0 (referent) 
1.1 (0.22-5.28) 
5.6 (1.41-22.55) 
9.9 (2.53-39.44) 
 
 
0.924 
0.014 
0.001 
MMA, nmol/L 
Q1 <199 
Q2 [199-297] 
Q3 [298-531] 
Q4 >531 
 
24 
25 
25 
25 
 
28 
41 
58 
45 
 
1.0 (referent) 
1.5 (0.48-4.76) 
1.4 (0.47-3.99) 
0.4 (0.138-1.43) 
 
 
0.48 
0.56 
0.17 
MTHFR genotypes 
MTHFR CC 
MTHFR CT 
MTHFR TT 
 
 
38 
47 
12 
 
86 
74 
12 
 
1.0 (referent) 
0.65 (0.28-1.48) 
0.14 (0.031-0.68) 
 
 
0.301 
0.014 
MTHFR/folate 
CC/folate ≥8.9 ng/ml 
CC/folate <8.9 ng/ml 
TT/folate ≥8.9 ng/ml. 
TT/folate< 8.9 ng/ml 
 
 
31 
7 
6 
6 
 
36 
50 
5 
7 
 
1.0 (referent) 
4.8 (1.56-14.5) 
0.8 (0.16-3.82) 
1.5 (0.31-6.99) 
 
 
0.006 
0.76 
0.63 
The model was adjusted for maternal age, gestational age, BMI, total parity, reported vitamin 
use, MTHFR,  and creatinine. Furthermore, MMA and folate were entered in the model for 
folate and MMA, respectively.  
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5. DISCUSSION 
 
The present study was carried out to investigate the role of HHcy and the underlying causes in 
preeclampsia in a population of Syrian pregnant women. B-vitamins status and other 
associated metabolites in 98 normal pregnant and in 177 preeclamptic Syrian women were 
analysed. Higher concentrations of Hcy, Cys, and MMA were closely linked to a lower status 
of the B-vitamins. Serum concentrations of folate and vit B6 were significantly lower and 
tHcy and Cys were significantly higher in preeclamptic as compared to normotensive women. 
Noteworthy, pregnant women were less likely to have folate deficiency (14 %), whereas a 
high prevalence of subnormal cobalamin status was found, indicated by elevated serum MMA 
(64.6 %) and low holoTC (77.7 %). HHcy (Hcy > 8.2 µmol/L) was seen in 65.2 % and 22 % 
of patients and controls, respectively. The findings underline that low B-vitamin status and 
HHcy are potential contributing factors for preeclampsia in Syrian pregnant women. 
                                                                                                                                                                              
5. 1. Homocysteine  
5. 1. 1. Hcy in normal pregnancy  
Normal range of tHcy in women was identified in several studies, with an accepted mean 
value of 9 µmol/L (Holmes et al., 2005; Murphy et al., 2004; 2002; Bates et al., 2002; Nygard 
et al., 1995). In the present study, healthy pregnant women were stratified into three 
subgroups according to the gestation age. First group included normotensive women with 
gestation age ≤ 34 wk, second group included normotensive women with gestation age 
between 35 and 38 wk, and the third group included normotensive women with gestation age 
> 38 wk (table 4. 11). As others have shown (Holmes et al., 2005; Murphy et al., 2004; 2002; 
Walker et al., 1999; Anderson et al., 1992), serum tHcy levels in normal pregnant women 
were lower (median value = 6.0 µmol/L) than that reported in non-pregnant women. Several 
explanation have been proposed for the lower tHcy concentrations in pregnancy (see above), 
but till now the exact mechanism is still not totally clarified.  
Through different tertiles of gestation age, serum tHcy demonstrated a significant increase: 
median values were 5.6, 6.4, and 8.0 µmol/L, respectively, (P < 0.001). Increased tHcy levels 
with increasing gestation were also found in other studies of a longitudinal design (Holmes et 
al., 2005; Ellison et al., 2004; Murphy et al., 2004). In these studies serum tHcy levels 
increased in the third trimester to reach its preconception levels at the onset of labour 
(Murphy et al., 2004), and two days after the delivery (Holmes et al., 2005). Some authors 
suggested that this elevation in tHcy plays a physiologic role in the preparation for labour, 
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since a significant influence of Hcy on the contractions of the myometrium has been recently 
reported elsewhere (Ayar et al., 2003). So far, the reason behind this elevation in tHcy during 
normal pregnancy is still unidentified. However, in the present study serum Hcy correlated 
negatively with serum folate and vit B12 and positively with MMA (table 4. 5, A). 
Additionally, asymptomatic women in late pregnancy had significantly higher level of MMA 
and lower levels of folate compared to those at earlier stage of gestation (table 4. 11). These 
findings suggest that vitamins depletion occurred in a part of the normotensive women 
throughout the pregnancy may contribute to the increase in tHcy levels seen in pregnant 
women (Milman et al., 2006; 2006 a). Of note, tHcy concentrations in normotensive women 
increased with increasing gestation by about 43 % (from 5.6 to 8.0 μmol/L). Increased tHcy 
concentrations was associated with decreased serum folate concentrations by about 46 % 
(from 18.6 to 10.1 ng/ml), whereas vit B12 concentration displayed a small decrease, about 17 
% (from 226 to 187 pg/ml) (table 4. 11). This indicates that increased tHcy levels in normal 
pregnant women is more influenced by the decline in serum folate concentrations rather than 
by vit B12 deficiency.  
 
5. 1. 2. Hcy in pregnancy complicated with preeclampsia 
Serum tHcy levels in preeclamptic women were significantly higher than those in 
normotensive counterparts (table 4. 3), with higher prevalence of HHcy (Hcy > 8.2 µmol/L) 
in patients (65.2 %) compared to controls (22 %) (figure 4. 1). Several studies have found 
elevated tHcy levels in preeclamptic women (Rajkovic et al., 1999; 1997; Leeda et al., 1998; 
Powers et al., 1998), while others did not (Herrmann et al., 2004; Hietala et al., 2001; 
Sorensen et al., 1999). Hcy metabolism is mainly influenced by B-vitamins availability 
(Murphy et al., 2004; McMullin et al., 2001; Andersson et al., 1992; Leeda et al., 1998) and 
renal function (Guttormsen et al., 1997). Therefore, higher tHcy levels in patients compared to 
controls could be related either to inhibited Hcy metabolism or to failure of mechanisms that 
lower Hcy during normal pregnancy. Since preeclamptic women had significantly lower level 
of folate and vit B6 compared to controls (table 4. 3) accompanied with renal changes, the 
possibility that Hcy was not actively catabolized in preeclamptic women seems more 
plausible (the relation between Hcy and either of B-vitamins or renal function will be 
discussed later). Furthermore, it is well accepted that the reference range for Hcy during 
pregnancy is lower than that in non-pregnant women. 
A recent study showed that women with higher tHcy levels in the preconception period were 
more likely to develop preeclampsia during their pregnancy (Ronnenberg et al., 2002). 
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Additionally, previous prospective studies demonstrated that elevated tHcy plasma levels may 
predict, in the early second trimester period, the subsequent development of preeclampsia 
(Cotter et al., 2001; Sorensen et al., 1999). Therefore, it may be argued that tHcy elevation 
precedes and predisposes to preeclampsia rather than being an indicator of preeclampsia. 
However, concentrations of tHcy in preeclamptic women of the present study and many 
previous reports were not in the range that may cause vascular damage. Additionally, reduced 
plasma volume and fluid loss from the intravascular compartment associated to preeclampsia 
may cause serum tHcy elevation. Furthermore, oxidative stress, which is reported to increase 
in preeclampsia (Hubel CA., 1999; Power et al., 1998) impairs selectively the MS function 
resulting in impairment of Hcy remethylation (McCaddon et al., 2002). The impairment of 
this metabolic function might explain the aetiology of HHcy seen in preeclampsia in several 
studies. 
 
In conclusion, normal pregnancy associated with increased tHcy level with increasing 
gestation, and Hcy metabolism was more influenced by folate status rather than by vit B12 
status. The significant lower folate and vit B6 concentrations in preeclamptic women suggest 
that Hcy in patients group was not actively catabolized. 
  
5. 2. B-vitamins 
5. 2. 1. Folate 
Serum folate concentration in normotensive women decreased significantly with increasing 
gestation with significant lower values in women in late pregnancy compared to those at 
earlier stages of gestation (table 4. 11). This decrease in folate concentrations may be 
explained, as others have suggested, by the accelerated breakdown of this vitamin because of 
its participation in cellular biosynthesis (Higgins et al., 2000; McPartlin et al., 1993), or by the 
pregnancy-related hemodilution (koebnick et al., 2001; Hall et al., 1976). Other studies 
showed that concentration of folate decreased from the fifth month of pregnancy onwards, 
and continue to decrease even at the post-partum stage (Lopez-Quesada et al., 2003; Ackurt et 
al., 1995; Bates et al., 1986). The highest catabolism rate of folate was seen in the third 
trimester where the maximal increase in fetal mass is occurred (Higgins et al., 2000). In 
contrast to normotensive pregnant women, serum folate concentrations in preeclamptic 
women did not decrease significantly during pregnancy (table 4. 11). However, the 
hemoconcentration associated to preeclampsia may hide such a decrease in serum folate 
causing, consequently, unrecognised folate deficiency (Koebnick et al., 2001).  
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Folic acid-supplemented women had significantly higher folate concentrations than un-
supplemented women in both groups (controls: 15.8 vs. 8.8, p = 0.048; patients: 8.5 vs. 5.7, P 
< 0.001). Additionally, other studies reported that maternal folate concentrations is mainly 
dependent on folate intake, and higher folate intake associated with higher serum folate 
concentrations (Ellison et al., 2004; walker et al., 1999; Bronstrup et al., 1998 a; Scholl et al., 
1996). Therefore, the lower folate concentration seen in preeclamptic women compared to 
controls is most probably because of increased folate requirements associated with lower 
folate intake. The present results showed that asymptomatic women took vitamin 
supplementation more frequently than preeclamptic women did (91 % of controls compared 
with 63 % of patients took supplementation, table 4. 1). More that, the duration of vitamin 
supplementation in normotensive women was significantly longer than that of patients 
(median duration of vitamin supplementation: controls = 19 wk; Patients = 8 wk, P < 0.001; 
figure 4. 5). Additionally, the consumption of folate, which acts as antioxidant by 
scavengering free radicals, as a response to increased oxidative stress in preeclmpsia increases 
the folate requirement and thus causes lower folate levels (Moat et al., 2006; Joshi et al., 
2001).  
Serum folate concentrations were significantly and inversely associated with Hcy in both 
groups (controls: r = - 0.41, p < 0.001; patients: r = - 0.32, p < 0.001). Lack or low level of 
folate inhibits the remethylation of Hcy into Meth resulting in elevated Hcy levels 
(Finkelstein JD., 1998). Thus, the higher tHcy levels in preeclamptic women may be partly 
explained by the significant lower levels of folate in patients compared to controls. Folic acid 
supplementation during pregnancy enhances RBC and serum folate status and the reduction in 
tHcy concentration (Holmes et al., 2005; Murphy et al., 2004; 2002). The present results do 
however confirm the reduction in Hcy levels due to folic acid supplementation (figure 4. 3). 
These findings are of great importance because reducing Hcy levels by folic acid 
supplementation is a safe and cheap policy and may reduce maternal complications associated 
to elevated tHcy levels (Hernandez-Diaz et al., 2002). Recently, folic acid supplementation 
was found to reduce the incidence of gestational hypertension (Hernandez-Diaz et al., 2002) 
and preeclampsia (sanchez et al., 2001).  
Despite that supplemented patients had serum folate concentrations similar to un-
supplemented controls (8.5 vs. 8.8 ng/ml), Hcy elevation was more pronounced in 
supplemented patients (10.0 vs. 8.3 µmol/L). This refers to that Hcy elevation seen in 
preeclamptic women is not entirely explained by lower folate status but other factors like 
renal function, combined low micronutrient status may be involved. Thus folic acid 
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supplementation alone was probably not sufficient to prevent Hcy elevation in women who 
developed preeclampsia. It is well established that folate and vit B12 may impact Hcy 
remethylation in an interactive manner (Obeid et al., 2002). Available data indicate that 
normal-to high-normal concentrations of serum folate are frequent in vit B12-deficient 
subjects (Herrmann et al., 2003 b) and unless both micronutrients are available, the 
accumulation of Hcy can not be prevented (Tefferi and Pruthi, 1994). 
 
5. 2. 2. Vit B12 
Serum vit B 12 concentrations gradually decreased throughout pregnancy. Decreased serum 
vit B12 concentrations was comparable in control and patient groups. In control, vit B12 
concentration decreased from a value which was shortly above the cut-off value of vit B12 
deficiency, reaching deficient concentrations in the third trimester, whereas vit B12 
concentration in preeclamptic women was pathologically lowered at earlier stage. Several 
studies reported decreased vit B12 concentrations with increasing gestation, and that about 
20-30 % of uncomplicated pregnancy associated with lower than normal serum vit B12 
concentration (Chery et al., 2002; Koebnick et al., 2002; Cikot et al., 2001, Ball and Giles, 
1964). The decreased vit B12 concentration throughout pregnancy was attributed to the active 
transport across the placenta (Monsen et al., 2001; Baker et al., 1958), changes in capacity 
and saturation of vit B12-binding proteins (Koebnick et al., 2002), and hemodilution 
(koebnick et al., 2001).  
Several authors suggested that decreased serum vit B12 concentrations during normal  
pregnancy does not necessarily indicate a vit B12 deficiency (Koebnick et al., 2002). The 
present results, however, argue against this suggestion. Along with decreasing serum vit B12, 
serum MMA concentrations displayed a significant increase (table 4. 11), confirming a 
gradual decline in the intracellular vit B12 concentrations. Elevated serum MMA 
concentrations were found in 57.6 % of the normotensive pregnant women, whereas 45.0 % 
had serum vit B12 < 211 ng/ml. Additionally, 22.0 % of normal pregnant women had elevated 
MMA levels despite normal serum vit B12 concentrations. Thus, in subjects with normal 
renal function, concentration of MMA is more sensitive in diagnosing an intracellular vit B12 
deficiency than the measurement of serum vit B12 concentration. Nevertheless, backward 
regression analysis showed that MMA level is significantly dependent on serum vit B12, but 
it is not specific parameter of intracellular vit B12 deficiency, since other factors had a 
significant influence on MMA levels (table 4. 10).    
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Concentrations of MMA in our subjects was much higher than values reported from American 
(Adams et al., 1995) or European pregnant women (McMullin et al., 2001; Monsen et al., 
2001). Similar metabolic abnormalities have been reported in pregnant women from other 
populations of poor socio-economic status (Guerra-Shinohara et al., 2004; Bondevik et al., 
2001). Pregnant women are at increased risk of developing subclinical vit B12 deficiency, 
particularly when pregnancy is associated with inadequate dietary intake of vit B12 (Chery et 
al., 2002). Serum MMA levels significantly increased in normotensive women with 
increasing pregnancy, and abnormal levels of serum MMA were seen in preeclamptic women 
at earlier stage of pregnancy (table 4. 11). These indicate a marginal preconception vit B12 
status associated with inadequate supply (Monsen et al., 2001). Serum MMA concentrations 
in preeclamptic women was influenced by several factors (table 4. 10), and these factors 
should be considered during estimation the vit B12 status depending on MMA levels. Firstly, 
backward regression analysis showed that creatinine independently and significantly 
influenced MMA concentrations. According to Rasmussen, MMA is eliminated by the 
glomerular filtration and passive reabsorption by the tubules, and conditions of renal 
insufficiency cause higher concentrations of MMA independent of vit B12 status (Rasmussen 
et al., 1990; 1989). Therefore, one may argue that glomerular endothelial cells damage 
characteristic of the kidney in preeclamptic women may cause higher concentrations of MMA 
independent of vit B12 status. But concentrations of MMA did not differ significantly 
between the preeclamptic and the control women at any time of gestation (table 4. 11). 
Therefore, it is more probable that MMA elevation is due to inadequate vit B12 status. 
Additionally, MMA correlated positively with Cys in preeclamptic women. Secondly, the 
condition of hemoconcentration or hypovolemia, like that seen in preeclampsia and thyroid 
disease are another possible reasons for light to mild elevation in MMA concentrations 
(Norman EJ., 1998). Unfortunately, in this regard the current study is limited. The GFR and 
maternal haematocrit values were not measured. Additionally, the interview-based 
questionnaires can not confirm the presence of any of diseases known to influence MMA 
levels. However, the low cobalamin status in the pregnant women of the current study is not 
unexpected because these women were taken from a population where vit B12 deficiency is 
endemic (Herrmann et al., 2003). 
 
5. 2. 3. Vit B6 
Normal pregnancy is associated with decreased maternal concentration of vit B6, particularly 
in the third trimester (Cleary et al., 1975; Shane and Contractor, 1975; Hamfelt and Tuvemo, 
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1972). According to Cikot et al. (2001) pregnancy induces a continuous decrease in pyridoxal 
phosphate concentration (the physiologically active vit B6), reaching about 23 % at the end of 
pregnancy. In the present study plasma vit B6 deficiency was found in a high frequency in 
both groups (85 % of controls and 89.8 % of preeclamptic women had plasma vit B6 < 4.3 
ng/ml). Decreased formation of pyridoxal-5′-phosphate in the liver or/and increased serum 
phosphatase activity, especially placental isoenzyme, contribute to the decreased plasma vit 
B6 during pregnancy (Barnard et al., 1987; Anderson et al., 1980). Additionally, the 
correlation analysis showed that vit B6 correlated significantly and inversely to gestation age 
(table 4. 5). A recent study showed that vit B6 was higher (6-fold) in the infants than in the 
maternal blood (Obeid et al., 2005). In order to maintain maternal plasma concentration 
within the normal range throughout pregnancy, American institute of medicine recommended 
a daily supplementation of 1.9 mg vit B6 during pregnancy, which is higher than the 
recommended dosage for nonpregnant women by 0.6 mg (Institute of Medicine, USA, 1999). 
In this context, Chang SJ. (1999) found that in healthy pregnant women a daily supplement of 
2 mg pyridoxine hydrochloride provides the adequacy of maternal and neonatal vitamin B6 
status and the satisfactory growth of neonates at birth. 
Plasma vit B6 concentrations were significantly lower in preeclamptic women compared to 
controls (2.0 vs. 2.4 ng/ml, P = 0.001). This result is in accordance with the results obtained 
by others. Brophy and Siiteri, (1975) found that pyridoxal phosphate concentrations in 
peripheral and cord blood obtained at the time of delivery were significantly lower in 
preeclamptic women compared to controls. Of note, the reported concentrations of PLP in 
their study were higher than the concentrations found in the present study, suggesting that 
Syrian pregnant women may have lower vit B6 status before pregnancy. Limit evidence is 
available regarding the role of vit B6 in preeclampsia (Vasdev et al., 1999; Brophy and Siiteri, 
1975). The administration of vit B6 during pregnancy has been reported to be beneficial  in 
decreasing the incidence of preeclampsia. Wachstein and Graffeo, (1956) found that a daily 
supplementation of a normal diet with 10 mg of pyridoxine hydrochloride during pregnancy 
caused significant decrease in the incidence of preeclmpsia (from 4-fold to 1.4-fold). Hillman 
et al. (1963) found however that the single supplementation with vit B6 had no influence on 
the incidence of preeclampsia.   
Serum vit B6 correlated inversely and significantly with Hcy only in patients group, 
indicating that decreased vit B6 concentrations is another possible reason, or participate 
together with other reasons, for tHcy elevation in preeclamptic women (Miller et al., 1992). 
Low vit B6 concentration impairs the production of the methyl group necessary for Hcy 
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remethylation by inhibiting the serin-hydroxymethyl-transferase enzyme in the folate cycle 
(Martinez et al., 2000), leading to a disturbed remethylation of Hcy and increased its serum 
concentrations. 
In case of vit B6 deficiency the degradation of Cys is inhibited more effectively than its 
synthesis resulting in Cys trap (Martinez et al., 2000; Ubbink et al., 1996). Plasma vit B6 
correlated significantly with Cys in both groups (table 4. 5). Despite that the median values of 
vit B6 in both groups were so far below the value which is commonly used as a primary 
indicator of PLP inadequacy, 20 nmol/L, Cys levels were significantly lower in normotensive 
women than in preeclamptic women (table 4. 3). This indicates sensitivity for vit B6 
deficiency in preeclamptic women which can be explained by the activation of 
transsulfuration pathway due to increased oxidative stress (Vitvitsky et al., 2003). The 
activation of transsulfuration pathway is an autocorrective response that leads to maintain or 
even to increase the intracellular glutathion pool in cells challenged by oxidative stress. The 
regression analysis showed that Cys concentrations were significantly and independently 
modulated by Hcy, creatinine, vit B6 and BMI in preeclamptic women, and by Hcy , vit B12, 
and vit B6 in normotensive women (table 4. 10). This data indicates that Cys level is not 
specific indicator for vit B6 deficiency, and in case of normal renal function, Cys is an 
indicator for B-vitamin deficiency in general. The absence of the relation between renal 
function and Cys in normotensive women confirms the importance of adequate renal function 
in controlling Cys levels in pregnancy.  
 
5. 3. Renal function and complicated pregnancy  
Serum creatinine concentrations were significantly higher in preeclamptic women compared 
to controls (0.71 vs. 0.57 mg/dl, p < 0.001), indicating a reduced glomerular filtration rate in 
patients group. It was reported that in pregnancy complicated with preeclampsia glomerular 
filtration rate (GFR) and renal plasma flow (RPF) decrease by 30 % to 40 % compared with 
normal pregnancy (Moran et al., 2003). This change in GFR was attributed to the abnormal 
glomerular morphology “endotheliosis” characteristic of preeclampsia (Robert JM., 1999). 
Kidney is provided with the whole necessary Hcy metabolising enzymes. According to 
Guttormsen et al. the renal uptake and metabolism of Hcy could account for approximately 70 
% of the daily Hcy elimination. Therefore, Hcy concentration is influenced by the renal 
clearance (Arnadottir et al., 1996).  
In the current study serum creatinine correlated highly significantly with Hcy (table 4. 6). 
This correlation confirms the role of the kidney as an important organ for Hcy metabolism. 
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Additionally, creatinine and Hcy are metabolically linked. The synthesis of creatinine from 
creatine is associated with simultaneous Hcy production (Stead et al., 2001; Mudd and Poole, 
1975). However, according to the current results the correlation of creatinine to Hcy seems to 
be due to the role of creatinine as a marker of GFR, and not due to its link to Hcy production. 
This is because creatinine lost its predictive value in normotensive women who had intact 
renal function and GFR, whereas it was one of the strongest predictors of fasting tHcy levels 
in preeclamptic women (table 4. 10).  
Increased serum concentrations of uric acid is usually used as a clinical marker in diagnosing 
preeclampsia (Yoneyama et al., 2002; Many et al., 1996; Hickman et al., 1982), and this 
elevation is correlated with the severity of disease (Pipkin and Roberts, 2000). Likewise, in 
this study serum uric acid levels were significantly higher in eclamptic women as compared to 
preeclamptic women (7.3 vs. 6.5 mg/dl, respectively, P < 0.001, data not shown). In normal 
situation uric acid is considered as a potent anti-oxidant. In the case of the depletion of other 
antioxidants, like in preeclampsia, it impairs the endothelial function by paradoxically acting 
as a pro-oxidant (Santos et al., 1999). Therefore, it is considered not only a marker of renal 
function but it is a risk factor for the progression of the disease, and recently was correlated 
with several prenatal complications (Yassaee F., 2003). 
Uric acid is freely filtered by the glomeruli with reabsorption in the proximal tubule. 
Increased levels of uric acid found in preeclampsia are due to an increase in proximal tubular 
reabsorption and a decrease of tubular secretion associated with decreased GFR (Conrad and 
Lindheimer, 1999). Foreman et al. suggested that the removal of Hcy in the normal kidney 
takes place in the proximal tubular cells (foreman et al., 1982). In this study uric acid 
correlated significantly to tHcy levels suggesting that the altered tubular function participates 
in the elevation of tHcy found in preeclamptic women. Nevertheless, the recent study of 
Yoneyama et al. suggested increased uric acid production due to increased activity of  plasma 
5`-nucleotidase enzyme in preeclampsia (Yoneyama et al., 2002). Therefore, one may argue 
that preeclamptic women in the current study have intact renal function and the significant 
elevation in tHcy concentrations in preeclampsia group is not explained by the impaired renal 
function. However, uric acid correlated highly significantly with creatinine in all groups and 
both were significantly higher in patients compared to healthy pregnant women (table 4. 2).  
In conclusion, mild renal dysfunction was an important determinant of tHcy, indicated by the 
positive correlation between creatinine, uric acid and tHcy. Therefore we can not exclude the 
possibility that preeclampsia related renal dysfunction accounts for Hcy elevations noted 
among cases versus controls. 
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5. 4. Effects of the interaction between MTHFR polymorphism, 
folate, and vit B12 on Hcy levels 
 
In this study the frequency of the T677 allele was 31.1 % which is comparable to the 
frequency reported in western population (Schneider et al., 1998). Lower tHcy levels seen in 
controls compared to preeclamptic women can not be attributed to a lower MTHFR T allele 
frequency. This because the frequency of the mutant allele did not differ significantly between 
controls and preeclamptic women (table 4. 7). Additionally, lower tHcy levels were even 
found in normal pregnant women comparing each MTHFR genotype independently (table 4. 
8). 
MTHFR enzyme catalyzes the conversion of CH2-THF to CH3-THF. The homozygous 
MTHFR TT genotype reduces MTHFR activity resulting in lower CH3-THF, the only methyl 
donor in the remethylation of Hcy into Meth, and higher tHcy levels. In the present study 
(table 4. 9), pregnant women with MTHFR TT genotype had significantly higher serum tHcy 
and lower folate levels than those with MTHFR CC genotype only when their serum folate 
levels were ≤ 8.9 ng/ml (this value represents the median folate in total population), and these 
differences disappeared when their folate concentrations were above the median, indicating 
that the influence of MTHFR TT genotype on tHcy and folate levels was modified by serum 
folate status. These results are in agreement with other studies (Bailey and Georg, 1999; 
Brattstrom et al., 1998), and gives a pattern of gene-nutrient interaction that influences tHcy 
levels in this population of Syrian pregnant women (Kim et al., 2004). One explanation for 
these observations is that higher folate status increases the stability of the mutated MTHFR 
enzyme, thus making its activity comparable to that of CC or CT, i.e., folate directly affects 
the mutated MTHFR enzyme (Jacques et al., 1996). Another explanation is that folate protects 
mutant enzyme against flavine adenine dinucleotide (FAD) loss, and consequently against 
thermal inactivation, i.e., indirect effect of folate (Hustad et al., 2000; Guenther et al., 1999). 
In addition to folate, a secondary gene-nutrient interaction between C677T-MTHFR and vit 
B12 has been postulated (Lucock et al., 2001). In the current study, a higher risk of HHcy was 
found in vit B12-deficient subjects with TT genotype compared with CC subjects who had 
higher vit B12 levels. The risk of HHcy in pregnant women with TT genotype increased to 
5.89 when TT pregnant women were within the highest quartile of MMA (table 4. 12). 
Nevertheless, the effect of the interaction between MTHFR and vit B12 did not reach the 
magnitude of the effect of the interaction between folate and MTHFR (table 4. 12). One 
explanation for this observation could be, as suggested by Herrmann et al. (2003 a), that vit 
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B12 is required in TT individuals for the reactivation of CH3-THF pool rather than for directly 
affecting the mutated MTHFR enzyme.  
In addition to folate and vit B12,  vit B2 is involved in the folate cycle as a cofactor required 
for the maximal catalytic activity of the MTHFR enzyme. High serum levels of vit B2 was 
found to attenuate HHcy due to MTHFR TT genotype. Additionally, animal studies showed a 
reduction in the activity of MTHFR and decreased the availability of 5-CH3-THF in the liver 
of vit B2-deficient rats (Bates and Fuller, 1986 a). Therefore, the measurement of vit B2, in 
combination with folate and vit B12, should be considered in the analysis of the influence of 
MTHFR genotype on tHcy concentration. Unfortunately, the present study is limited in this 
point where no measurements of serum vit B2 are available. 
In conclusion , the present study showed that tHcy concentrations did not differ significantly 
with the MTHFR genotype, and the influence of TT on tHcy levels was modulated by folate 
and vit B12 status as TT subjects with low folate and vit B12 status had increased risk of 
HHcy. 
  
5. 5. MTHFR polymorphism, folate, vit B12, and the risk of 
preeclampsia 
 
It is hypothesised that MTHFR 677 C→T is a potential risk factor for preeclampsia (Online 
Mendelian Inheritance, OMIM). Table 4. 13 showed that MTHFR genotype was not 
associated with the risk of preeclalampsia, which argues against the usefulness of maternal 
MTHFR polymorphism in predicting the risk of preeclampsia among pregnant women of the 
present study. Several investigators have found an association between MTHFR 677 C→T 
and the risk of preeclampsia (Grandone et al., 1997; Sohda et al., 1997), whereas others did 
not (Yilmaz et al., 2004; Prasmusinto et al., 2002; Zusterzeel et al., 2000; Powers et al., 1999). 
In contrast to MTHFR 677 C→T polymorphism, increased risk of preeclampsia was 
associated with increased levels of tHcy. Women with tHcy levels above 7.8 μmol/L were 
21.6 times more likely to have preeclampsia compared with women whose tHcy levels were 
lower than 5.2 µmol/L (table 4. 13). Additionally, maternal folate concentrations had a 
significant role in preeclampsia risk. The calculated odds ratio (OR) for preeclampsia risk for 
different quartiles of folate concentrations showed a higher risk of preeclampsia at lower 
folate concentrations, with odds ratios ranging from 1.1 in the third quartile to 9.9 in the 
lowest quartile. Furthermore, we found that the risk of developing preeclampsia in women 
with CC genotype increased from 1 to 4.8 in the presence of low folate, while the risk 
increased in women with TT genotype only from 0.8 to 1.5 with low folate (table 4. 13). This 
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adds further evidence that the risk of preeclampsia was not associated with the MTHFR 
genotype. Higher serum MMA levels, however, were not associated with an elevated risk of 
preeclampsia, which is in consistent with previous studies (Sanchez et al., 2001; Rajkovic et 
al., 1997). Several studies found no association between maternal serum folate and the risk of 
preeclampsia (Powers et al., 1998; Rajkovic et al., 1997). The OR associated to decreased 
maternal folate concentration is lower than that associated with higher tHcy levels. This 
observation may be explained by the role of folate as antioxidant and its inverse relationship 
to Hcy (Selhub et al., 1993), Whereas HHcy is known to promote endothelial dysfunction, 
thereby increasing the risk of preeclampsia (Robert and cooper, 2001; Roberts et al., 1999). 
Due to the retrospective design of this study it was not possible to determine whether these 
differences in maternal tHcy and folate levels are causal for preeclampsia or caused by 
preeclampsia. However, a prospective study by Sorensen et al. demonstrated that Hcy-
elevation precedes preeclampsia by approximately 8-16 weeks (Sorensen et al., 1999). 
In conclusion, low maternal folate concentration and high Hcy levels were associated with an 
increased risk of preeclampsia. Results from the present study and few other (Sanchez et al., 
2001; Rajkovic et al., 2000; Ray and Laskin, 1999) suggest that folic acid and other B 
vitamins may be important in the pathogenesis of preeclampsia. 
 
5. 6. Limitations and strengths of the study 
The results obtained from this study must be interpreted with some caution due to several 
limitations. First, the patients and controls were not matched for the gestation age which was 
later in the control group than in patients group. Changes in maternal tHcy levels according to 
the gestation age were reported in several studies (Holmes et al., 2005; Murphy et al., 2004; 
Walker et al., 1999). However gestation age correlated significantly with tHcy in controls but 
not in patients group. Therefore, the higher gestation age in patients compared to controls (37 
vs. 35 wk; P < 0.05) can not explain the elevated tHcy levels found in patients. Because the 
blood pressure of the pregnant women was not the outcome of interest in the present study, 
the individual values of blood pressure in the normal pregnant women were missed (table 4. 
1). However, the controls selection was based on the available data registered by the resident 
doctors, which insured the normal blood pressure of the selected women.   
  
One strength of the current study is that subjects were homogenous group of Syrian women. 
of similar educational background and socio-economic status. Therefore, ethnicity as a 
possible confounder for preeclampsia is excluded in this study (Eskenazi et al., 1991). 
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Moreover, by use of the questionnaire, important information about diet and lifestyle factors 
such as smoking, coffee or/and alcohol consumption, and exercises could be obtained. These 
factors are known to influence the biochemical factors (Nurk et al., 2004; de Bree et al., 
2001). It was reported that B-vitamins status in women varied significantly depending on the 
season in which blood was sampled (Jiang et al., 2005; Ronnenberg et al., 2000). These 
variations were attributed to the seasonal variations in the availability of B-vitamins-rich 
foods. In order to avoid this variation in B-vitamins status, the blood samples of normotensive 
women were collected in parallel to the blood samples of the preeclamptic women. Other 
important strength is that blood samples were collected from women who had fasted for at 
least 12 hours. This point of importance because dietary factors may affect circulating tHcy 
levels (Ueland et al., 1993). 
 
The current study and few others (Wannous and Arous, 2001; Bakour et al., 1998) included 
socioeconomically disadvantaged Syrian women admitted to cost-free hospitals operated by 
the Syrian government. These women were also of low education level and were not likely to 
visit antenatal care services at early pregnancy. Therefore, these data might probably not 
reflect the nation wide situation. However, folate, vit B12, and vit B6 intakes should be 
increased in women of childbearing age from this population. 
 
Taken together, the present study refers to a high incidence of HHcy in Syrian preeclamptic 
women. HHcy was closely related to a poor nutritional status (folate, vit B12, vit B6). The 
limited effect of folate supplementation on serum concentrations of Hcy was partly related to 
a short duration of usage. Folate effect on Hcy level was also counterbalanced by a low status 
of vit B12 and B6. Further studies should clarify the impact of combined vitamin 
supplementation on some pregnancy complications and outcome, including preeclampsia, pre-
term deliveries and low birth weight. Finally, the effect of poor maternal nutritional status on 
some health aspects of the newborns needs further investigations. 
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